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 Muscles give our bodies the ability to move by stretching and contracting. While 
contraction is accomplished by the well-known actin-myosin interaction, not much is known 
about stretch.  Two integral muscle proteins involved in stretch are titin and obscurin; both are 
long rope-like protein molecules that seem to act as molecular springs. Mutations in these two 
proteins can lead to diseases such as hypertrophic cardiomyopathy and muscular dystrophy, as 
well as a variety of cancers. In an effort to understand muscle stretch and signaling on a more 
fundamental level, here we present the high resolution structure of obscurin Ig59, a domain 
involved in titin/obscurin binding. We also describe how unbound titin moves when stretched. 
Last, we describe ongoing work in elucidating the high-resolution structures and 
activation/inhibition mechanisms of obscurin domains Rho-GEF, Rho-GEF-PH, kinase I (KI), 







Muscles, Muscle Proteins, and Structure of the Sarcomere 
 Muscles give our bodies the ability to move by stretching and contracting. Without 
them, we would not be able to walk, stand up, or perform any of the motions do throughout our 
daily lives. Striated muscles, the ones connected to our skeleton, allow for virtually all 
voluntary movement of our body. As the name implies, this kind of muscle is made up of a 
series of different bands that are visible in the light microscope, termed the A-band and the I-
band. One A-band and half of the neighboring I-band form the sarcomere, the smallest 
contracting segment of muscle. Hundreds of sarcomeres lie end-to-end, making up the syncytial 
cell type called the myofibril. These cell types are the largest in the human body; the longest 
can be more than a foot long. Many myofibrils are bundled together into a single fascicle, 
which in turn is bundled into a muscle (Fig. 1).  
 
 When a muscle 
contracts, myosin thick 
filaments slide across F-actin 
thin filaments in an ATP- and 
calcium-requiring reaction, 
resulting in a shortening of 
the sarcomere. This process, 
termed the sliding filament 
model, involves a number of 
simple steps to produce 
contraction. When the brain 
generates an electrical signal 
in the form of an action 
potential, it courses along 
through the somatic nervous 
system to the axon of a motor 
neuron, which is connected to 
a skeletal muscle cell. 
Acetylcholine is released by 
neurotransmitters within the 
Figure 1. Schematic representation of the muscle, showing its breakdown into fascicles, fibers, and 
sarcomeres (adapted from John Wiley & Sons, Inc., 2013). 
Figure 2. Steps of muscle contraction showing the process of 
calcium release and binding to troponin, conformation changes of 
troponin and tropomyosin, hydrolysis of ATP, power stroke, 
binding of ATP to myosin, and release of bound calcium from 





synaptic cleft, which binds to membrane proteins in the outer layer of the muscle cell, 
depolarizing it. This depolarization allows the action potential to travel into the cell and activate 
Ryanodine receptor-dependent calcium channels within the sarcoplasmic reticulum. Calcium 
ions flow into the muscle cell as a result and bind to troponin in the thin filament region of the 
muscle cell. The calcium binding induces a conformation change in the troponin protein, which 
in turn alters the tropomyosin-actin interaction. The new conformation of tropomyosin exposes 
the myosin binding sites on actin (the thin filament). Once the myosin binding sites are 
exposed, head structures on the myosin molecules hydrolyze bound ATP and reorient to bind to 
actin. Finally, release of ADP and Pi from the myosin head generates a power stroke (Fig. 2, 
steps 1 and 2) that brings adjacent Z lines closer to each other, shortening the length of the 
sarcomere and contracting the cell (Fig. 2, step 3. The cell returns to a relaxed state when ATP 
binds to myosin and the calcium ion bound to troponin is released (Fig. 2, step 4). 
 In order for these ultrastructural filaments to perform their jobs and contribute to overall 
muscle contraction, the sarcomere must be exquisitely well ordered. If the thick filaments did 
not interdigitate the thin filaments, there would be no contraction. Similarly, if the thick and 
thin filaments did not overlap, there would be no power stroke. The almost paracrystalline-like 
array of contractile apparatus is accomplished through the cytoskeleton; particularly, through 
the involvement of the giant cytoskeletal proteins titin, nebulin, and obscurin. 
 Titin, the longest known polypeptide at 3-5 MDa, has its N- and C-termini anchored in 
the Z-disc and M-line, respectively. Titin generates passive elasticity of muscles by acting as a 
force sensor and regulates the length of the thick filament of the sarcomere (Trinick, 1992; Hsin 
et al., 2011; Fig. 3, red). Throughout its considerable length, it binds to and anchors many 
proteins to the surrounding cytoskeleton and acts as a molecular spring, regulating amount of 
stretch in the sarcomere. Nebulin (600-800 kDa) stabilizes the thin filament and may also have 
some function in regulating the length of the thin filament, directing actin/myosin interactions, 
and myofibrillar force generation (Trinick, 1992; Chu et al., 2016; Kontrogianni-
Konstantopoulos et al., 2009). Last, obscurin connects the sarcomere to the surrounding 
sarcoplasmic reticulum via its interaction with titin (Fig. 3) and aids in assembly of myofibrils 
and the sarcoplasmic reticulum (Meyer and Wright, 2003; Lee et al., 2010; Bang et al., 2001; 
Young et al., 2001; Armani et al., 2006; Kontrogianni-Konstantopoulos and Bloch, 2009). 
Obscurin and titin are the focus of 
my research. 
 Due to their large size and 
complexity, titin and obscurin have 
been difficult to study using 
traditional molecular biology or 
biochemistry techniques. However, 
both are highly modular in overall 
architecture. Titin has 
approximately 300 independently 
folded domains while obscurin has 
at least 70, though the exact number 
depends on the isoform; each 
domain of titin consists of 
approximately 100 amino acids 
(Meyer and Wright, 2013). The 
most common folds are the 
immunoglobulin (Ig) and 
Fibronectin typeIII-like (FnIII-like) 
domains, which both fold into 
variations of a β-sandwich fold. 
Figure 3. Schematic representation of the sarcomere. Titin (red) 
anchors the M-line and Z-disc and regulates the length of the 
sarcomere. Obscurin (blue) tethers titin to the sarcoplasmic 
reticulum. Nebulin (green) regulates the length of the thin 
filaments (actin, under the green). Myosin heads (grey) slide 
across the thin filaments as a muscle contracts (taken from 




(Meyer and Wright, 2003; Fig. 4). Rather than trying to discern structure/function relationships 
of the entire obscurin or titin molecule, we (and others) have instead found it more useful to 
focus on solving the high-resolution structure of individual domains. In other words, we choose 
to describe the obscurin and titin structure/function relationship from a bottom-up approach, 
from domains to whole molecules. To this end, I will begin with an overview of titin and 







and spans the 
sarcomere 
from the Z-
disk to the 
M-band 




Linke, 1994; Kontrogianni-Konstantopoulos et al., 2009). In the body, titin regulates the length 
of the sarcomere and helps restore the pre-contraction length, protecting the sarcomere from 
injury caused by overstretching (Lee et al., 2010). Titin’s ability to both stretch and recoil is 
fundamental in preventing muscle overstretching, and helps myocytes return to their original 
length (Gautel, 2011; Improta et al. 1998). In this capacity, titin acts as a mechanosensor 
(Kontrogianni-Konstantopoulos et al., 2009; Linke 2008; Meyer and Wright, 2003). 
 
Figure 5. Schematic representation of the structure and binding partners of titin A-M (the portion of titin 
spanning from the A-line to the M-line). Note that the key provided lists the domain types as well as the 
meaning of the colors and shapes used in the schematic (adapted from Kontrogianni-Konstantopoulos, 
2009). 
 A decidedly important player in muscle contraction, titin has a multitude of binding 
partners, one of which is obscurin (Fig. 6). Obscurin (~720-900 kDa) is made up of mostly Ig 
domains and binds to titin in the Z-disk region of the sarcomere (Young et al., 2001; Bang et 
al., 2001) (Fig. 5&6). With titin bound at its N-terminus and small ankyrin bound at its C-
terminus, obscurin effectively connects titin to the sarcoplasmic reticulum (Bang et al., 2001; 
Young et al., 2001; Armani et al., 2006; Kontrogianni-Konstantopoulos et al., 2009) (Fig. 6). 
Figure 4. Cartoon representation and schematic of A.) an Ig domain and B.) a FnIII-
like domain. The cartoon representations are colored from N-terminus (blue) to C-





Figure 6. Schematic representation of the structure and binding partners of the two main isoforms of 
obscurin, isoforms A and B. Note that the key provided lists the domain types as well as the meaning of 
the colors and shapes used in the schematic (adapted from Kontrogianni-Konstantopoulos, 2009). 
 The OBSCN gene is located on human chromosome 1q42 (Fukuzawa et al., 2005). 
Obscurin A is encoded by this gene and all other obscurin isoforms result from alternative 
splicing of this gene (Russell et al., 2002; Fukuzawa et al., 2005; Kontrogianni-
Konstantopoulos et al., 2009). Obscurin is found mostly in skeletal and cardiac muscle tissue, 
though it has also been found in the brain and in breast epithelial tissue (Nagase, 2000 (1-3); 
Stroka et al., 2016; Perry et al., 2014; Shriver et al., 2016). The two largest, muscle-specific 
isoforms are obscurin A (~720 kDa) and obscurin B (~870 kDa). These two isoforms differ 
only at the C-terminus: obscurin has a non-modular C-terminus with binding sites for small 
adaptor proteins called ankyrin and obscurin B has adhesion motifs superseded by two terminal 
serine-threonine kinases (Ackermann et al., 2014; Fukuzawa et al., 2005). Obscurin B has more 
signaling moieties and, because obscurin has been known to directly phosphorylate substrates 
in the body, this lab uses obscurin B in its experiments (Shriver et al., 2016; Perry et al., 2014; 
Hu and Kontrogianni-Konstantopoulos, 2013). 
 Mutations in the regions close to 
obscurin/titin interactions are associated with 
pathogenesis of muscle diseases, namely 
muscule wasting diseases such as muscular 
dystrophy (MD) (Hackman et al., 2002; Zheng 
et al., 2015) and malformed muscle diseases 
like hypertrophic cardiomyopathy (HCM) 
(Satoh et al., 1999; Fukuzawa et al., 2005). MD 
is a group of inherited diseases in which 
muscles become damaged and progressively 
weaken. As a result, the body is unable to 
increase muscle mass or repair damaged muscle 
and the muscle may eventually die (Fig. 7). 
Affected muscles can include skeletal and 
cardiac muscles, which can lead to problems 
with posture, ambulation (walking), cardiac, 
and respiratory function (McNally and Pytel, 
2007). HCM, on the other hand, is characterized 
by a left ventricular hypertrophy with diastolic 
dysfunction, all of which are caused by mutations in genes that code for proteins in the Z-band 
of the sarcomere (Arimura et al., 2006; Frenneaux, 2004). In HCM, there is an asymmetric 
accumulation of poorly functioning, enlarged, cardiomyocytes, specifically in the left ventricle, 
which results in a constricted, generally malfunctioning heart (Fig. 8; Elliot and McKenna, 
Figure 7. Normal muscle (left) next to a 
muscle with muscular dystrophy (right). In the 
muscle with MD, the muscle had begun to 




2004; Teekakirikul et al., 2012). HCM accounts for 1% of annual mortality rates and can cause 
death from sudden cardiac death, heart failure, or stroke (Frenneaux, 2004). 
 Obscurin mutations and pathogenesis of 
muscle diseases are not as well studied as their 
counterparts in titin. In fact, only a single study 
involving a single example has been published 
(Arimura et al., 2007). In this study, the R8 to 
Q8 (Arg4344Gln) mutation in Ig58 was linked 
to HCM. This mutation occurs in the OBSCN 
gene in the region of that codes for the 
titin/obscurin binding site and, as such, causes a 
decreased binding affinity of obscurin to titin 
(Arimura et al., 2007; reviewed in 
Kontrogianni-Konstantopoulos et al., 2009). In 
an unpublished study, a single mutation in 
obscurin was linked to MD: R16 to W in Ig59 




In order to understand the causes of these diseases on the molecular level, the wild-type and 
mutated structures of these individual domains must be studied, elucidated, and compared. High 
resolution structures of individual domains can be determined via nuclear magnetic resonance 
(NMR) spectroscopy and X-ray crystallography. 
 X-ray crystallography first requires the growth of a single protein crystal, a periodic 
assembly of protein molecules held together in a regularly-repeating lattice network by weak 
molecular forces (Rupp, 2010). This can be accomplished through methods such as hanging 
drop vapor diffusion, sitting drop, or microbatches (Rupp, 2010; Dessau and Modis, 2011). 
Once the crystals are grown, they are harvested and kept frozen until data collection, generally 
by use of a synchrotron. The structure of the repeating units within the crystal can be 
determined by analyzing the diffraction of high energy electromagnetic radiation by the 
electron density within the crystal lattice in the form of the crystal’s X-ray diffraction pattern. 
When X-ray photons encounter these electrons, they are scattered at specific angles, whose 
points or positions can be interpreted as reflections from sets of discrete lattice planes. This is 
partially because the X-ray wavelength used is comparable to the interatomic distances in the 
molecules studied (Wladawer et al., 2013). The angle of scattering is related to the distance 
between planes h, k, and l by Bragg’s law, given below. 
nλ = 2dhklsinθ 
In which dhkl is the lattice plane spacing, n is the order of reflection, and θ is the scattering 
angle.  
 The scattering function (𝑓𝑠 or 𝐹𝑠) can give the approximate X-ray scattering of an entire 
system where Fs depends on the direction of scatter and, therefore, on the angle of scatter. For a 
single atom, the X-ray scattering is very small and is given by: 




Figure 8. Normal heart (left) next to a heart 
with hypertrophic cardiomyopathy (right). In 
the heart with HCM, the cardiac muscles 
have enlarged and decreased the area 




In which ρ(r) is the electron density, r is the position of an electron in the atom, S is the 
scattering vector— the difference between the incoming and scattered wave vectors— and 
V(atom) is the volume of the atom. For a larger, repeating structure such as a molecular crystal 
lattice, the scattering function is described as a sum of the scattering functions of individual 
atoms: 





In which 𝐹𝑠 is the scattering function of the crystal and 𝑓𝑠
0 is the atomic scattering factor. 
 The X-ray diffraction pattern can also be interpreted as transforming the crystal 
structure’s electron density from real space ℝ (x, y, z) to reciprocal space ℝ* (h, k, l). In 
reciprocal space, the scattering function of a molecular crystal becomes: 





In which 𝐹ℎ is the scattering function in terms of the index vector ℎ, 𝑥 denotes the position of 
an atom/electron in an atom in fractional coordinates, and, by extension, 𝑥𝑗 denotes the position 
of the 𝑗th atom/electron (Rupp). Such a transformation from real to reciprocal space is termed a 
Fourier transform and can be generalized with the form: 




a complex Fourier integral, derived as an eigenfunction of the Sturm-Liouville eigenvalue 
problem with periodic boundaries (Rupp, 2010). There is an inverse relationship between the 
spacing of reflections in a diffraction pattern and the spacing in the original crystal lattice, 
which can be used to establish the dimensions of a unit cell within the crystal lattice (Rhodes, 
2006). 
 The points of a diffraction pattern give the relative intensities of scattering as well as the 
position. Because the structure of the unit cells of a crystal repeats periodically to form a lattice, 
the incoming photon waves that scatter as a result of an electron cloud encounter each other and 
can interfere constructively, destructively, or partially, resulting in an enhancement or 
quenching of X-ray radiation that is depending on the direction of the wave vector (Wlodawer 
et al., 2008; Wlodawer et al., 2013). These intensities are related to the complex structure factor 
(𝐹) in the following way: 
𝐼 = 𝐹𝐹∗  =  |𝐹|2 
 Because F is a wave equation, it must specify the frequency, amplitude, and phase of 
each diffracted ray (Rhodes, 2006). But, in calculating the amplitude of the structure factor to 
gain information about the intensities of a reflection, all information about the phase angle of 
each reflection is lost. This significantly encumbers the reconstruction of molecular structure, 
which requires an understanding of the phases of a reflection (Rupp, 2010). The remedy to this 
problem will be discussed later. 
 The size of the unit cell of a crystal lattice is directly proportional to the number of 
diffracted beams, and, therefore, is directly proportional to the number of reflections and 
reflection intensity observed. Also, due to the symmetric nature of crystals, multiple individual 




to a certain redundancy or multiplicity factor. The higher the multiplicity factor, the more 
accurate the average reflection intensity, since all individual reflections have an innate degree 
of random error (Wlodawer et al., 2013). The value Rmerge reports the agreement of all 
symmetry-equivalent reflections that contribute to the same unique reflection and is given by: 
𝑅𝑚𝑒𝑟𝑔𝑒 =  ∑ ∑|< 𝐼ℎ > −𝐼ℎ,𝑖| ∑ ∑ 𝐼ℎ,𝑖
𝑖ℎ𝑖ℎ
 
In which h represents the unique reflections, i represents the symmetry-equivalent contributors 
to each unique reflection, and < 𝐼ℎ > represents the average intensity of each reflection 
(Wlodawer et al., 2013; Wlodawer et al., 2008). In other words, Rmerge compares the average 
intensity of the original model with the intensity of the current model and therefore is an 
indicator of bias, and, consequently, potential inaccuracies. Rmerge can also be written as: 
𝑅𝑚𝑒𝑟𝑔𝑒 =  







In which N represents all redundant measurements for each individual reflection h (Rupp, 
2010). Ideally, a high-quality diffraction pattern would have an Rmerge of ≤5% (Wlodawer et 
al., 2013; Wlodawer et al., 2008). However, in reality, the Rmerge may be slightly higher, though 
it is generally less than 20% for large biomolecules (Rupp, 2010). Additionally, the signal to 













Where an acceptable range of < 𝐼/𝜎(𝐼) >  is ≤1.5-2.0 (Rupp, 2010). 
 In short, from the diffraction pattern, it is possible to gain the positions and intensities of 
individual reflection but not their phases. The inability to garner phases from diffraction data 
gives rise to the ‘phase problem’ of crystallography. Phases can be supplied by other means, 
such as isomorphous replacement, anomalous scattering, and molecular replacement. The 
research in this thesis was conducted using molecular replacement. 
 Molecular replacement uses the phases and structure factors from previously solved, 
similar protein structures, called phasing models, to obtain the phases of the target protein. For 
example, most if not all immunoglobulin domains are comprised of very similar structures (see 
Fig. 6). Therefore, it is feasible to use phases from other immunoglobulin domains to estimate 
the phases of an unsolved immunoglobulin domain; generally an immunoglobulin phase model 
requires a minimum of 30% sequence identity (Scapin, 2013; Chothia and Lesk, 1986). In this 
case, the two structures are isomorphous, or share the same crystal structure. The electron 
density, 𝜌(𝑥, 𝑦, 𝑧), of the target structure can be calculated from those of the isomorphous 
phasing models by the following equation: 









In which V is the volume of the unit cell, 𝐹ℎ,𝑘,𝑙
𝑡𝑎𝑟𝑔𝑒𝑡
 is the amplitudes of the scattering function of 
the target protein, 𝛼′ is the phases of the model, and the frequencies h along the x-axis, k along 
the y-axis, and l along the z-axis are given by hx, ky, and lz, respectively (Rhodes, 2006). Using 




the overall structure. To this, the target sequence of amino acids can be fit, giving a model of 
the overall structure. Given that the first output map will be crude, because the phases of the 
model are only rough estimates, both the map and model will require iterative manual and 
computational improvement. However, due to the implementation of the phasing model, a great 
potential for bias was also introduced— that the calculated phases from the model, rather than 
the observed phases from the experimental intensities, would dominate the outputted map. To 
prevent model bias, a new map can be generated by obtaining a contour in which the calculated 
structure factor amplitudes (|𝐹𝑐𝑎𝑙𝑐|) are subtracted from multiple observed structure factor 
amplitudes (𝑛|𝐹𝑜𝑏𝑠|): 
𝜌(𝑥, 𝑦, 𝑧) =  
1
𝑉






′  is the phases of the model. The map generated from the previous equation is 
known as a 𝐹𝑜 − 𝐹𝑐 map or basic difference map and gives regions of positive and negative 
densities that require moving atoms towards or away from the regions, respectively (Rhodes, 
2006; Rupp, 2010). An amino acid in an unfavored conformation according to the 𝐹𝑜 − 𝐹𝑐 map 
will have negative density at its current conformation and positive density nearby, where its 
preferred conformation would fit. 
 𝐹𝑜 − 𝐹𝑐 maps rely solely on the original data and eliminate bias from the current model 
so that the errors in it can be determined. Since 𝐹𝑜 − 𝐹𝑐 maps point out the errors of the current 
model, it is often not useful for the beginning stages of reconstruction, when there are more 
errors, because the output is ‘noisy’ and difficult to read. Therefore, a  2𝐹𝑜 − 𝐹𝑐 map or 
combined difference map is more often used, which allows a greater influence from the model 
but gives a more easily understood map. 2𝐹𝑜 − 𝐹𝑐   maps are given by: 
𝜌(𝑥, 𝑦, 𝑧) =  
1
𝑉





 Through the process of model and map refinement, the particular conformation(s) of 
each amino acid will be found and corrected through adjustment of variables such as clash 
scores and χ and φ angles, definition of the electron density map, and decrease R-factor values, 
which are defined as: 
𝑅𝑓𝑎𝑐𝑡𝑜𝑟 =  
∑ ∑ ∑ |𝐹𝑜𝑏𝑠 − 𝐹𝑐𝑎𝑙𝑐|𝑙𝑘ℎ
∑ ∑ ∑ 𝐹𝑜𝑏𝑠𝑙𝑘ℎ
 
 There are a variety of R-factors, including the linear merging R value, 𝑅𝑚𝑒𝑟𝑔𝑒, defined 
previously, which compares the average intensity of the original data and current model, and 
the cross validation R value, 𝑅𝑓𝑟𝑒𝑒, which is calculated the same as the normal R-factor but 
only for approximately 10% of the original data points. 𝑅𝑓𝑟𝑒𝑒 is given by: 
𝑅𝑓𝑟𝑒𝑒 =  
∑ |𝐹𝑜𝑏𝑠 − 𝑘𝐹𝑐𝑎𝑙𝑐|ℎ𝜖𝑓𝑟𝑒𝑒
∑ 𝐹𝑜𝑏𝑠ℎ𝜖𝑓𝑟𝑒𝑒
 
Where ℎ𝜖𝑓𝑟𝑒𝑒 denotes the excluded cross-validation set (Rupp, 2010). A high-resolution 
crystal structure is defined by an 𝑅𝑓𝑟𝑒𝑒 < 20%, a resolution of 0.86–1.5 Å, and an 𝑅𝑚𝑒𝑟𝑔𝑒 <
~4%, though, practically, these values may deviate (Wlodawer et al., 2008). At this point, a 




 In this work, the high resolution structure of obscurin Ig59 was obtained. Work is in 
progress for the elucidation of high resolution structures of obscurin domains Rho-GEF, Rho-





A Variant in the Obscurin Gene Associated with a Frameshift Mutation in the Filamin C 
Gene in a Family with Distal Muscular Dystrophy* 
*This chapter is based on a manuscript that has been submitted to PLoSONE. The writing of 
this chapter was a joint effort between our lab and our collaborators in Italy. 
 
Introduction 
 Distal muscular dystrophies are a group of inherited primary muscle disorders showing 
progressive muscle atrophy and weakness, usually in the hands and/or feet (Mutoni and Wells, 
2007; Ng et al., 2012; Sewry, 2010; Udd, 2012). These dystrophies have diverse etiologies, and 
are further classified via one of four methods:  i) clinical features, i.e. early or late adult onset, 
onset in the hands or feet; ii) magnetic resonance imaging (MRI)-based evidence of an 
involvement of the 
anterior or posterior 
compartment of the 
legs; iii) inheritance 
pattern; and/or iv) 
histopathological 
findings (Udd, 2012; 
Mastaglia and 
Laing, 1999). Here 
we will use a 
combination of all 
four classification 
schemes to describe 
a new gene member 
(obscurin) that 
appears to be 
autosomally-linked  
with late onset of 
distal muscular 
dystrophy (see 
Table 1 for a 







which the mutated 
genes often encode 
sarcolemmal 
proteins, many of 
the genes identified 
in distal muscular 
dystrophies encode 
proteins associated 
Type of Distal Muscular Dystropy Associated Gene 
Autosomal Dominant: Late Onset   
TIA1 Mutated Welander Distal Myopathy TIA1 
Titin Mutated Tibial Muscular Dystropy TTN 
Distal Myotilinopathy MYOT 
ZASPopathy LDB3 
MATR3 Mutated VCPDM MATR3 
VCP Mutated Distal Myopathy VCP 
aB-crystallin mutated distal Myopathy CRYAB 
Thenar Atrophy with Sarcoplamic Bodies FHL1 
Mutated Distal Myopathy SQSTM1 
Autosomal Dominant: Adult Onset   
Desminopathy DES 
ABD-FLNC Mutated Distal Myopathy ABD-FLNC 
DNAJB6 Mutated Distal Myopathy DNAJB6 
HSPB8 Mutated Neuromyopathy HSPB8 
Finnish MPD3 No known gene 
Oculopharyngeal Distal Myopathy No known gene 
Autosomal Dominant: Childhood Onset   
Distal Myosinopathy MYH7 MYH7 
KLHL9 Mutated Distal Myopathy KLHL9 
Autosomal Recessive: Early Adult Onset   
Miyoshi Dysferlinopathy DYSF 
Distal Anoctaminopathy ANO5 
GNE Myopathy GNE 
Recessive Distal Titinopathy TTN 
Autosomal Recessive: Childhood Onset   
Distal Nebulin Myopathy NEB 
ADSSL Mutated Distal Myopathy ADSSL1 
Oculopathyngeal Distal Myopathy PABPN1 





with the contractile apparatus and Z-disk of the sarcomere (Udd, 2012; Udd, 2001). Both 
dominant and recessive mutations in the titin gene (TTN) have been associated with human 
distal dystrophies (Evilä, 2014). Titin is the largest protein of the sarcomere extending from the 
Z-disk to the M-line. A number of sarcomeric and signalling proteins interact with titin (Gautel, 
2011). Among these, obscurin, another giant myofibril-associated protein, interacts with titin at 
both the M-band and the Z-disk (Chauveau et al., 2014; Young et al., 2001; Fukuzawa et al., 
2008; Gautel and Djinović-Carugo, 2016; Rudloff et al., 2015). Mutations in the M10 domain 
of titin, which binds the Ig1 domain of obscurin, cause tibial muscular dystrophy (TMD) or 
Udd myopathy in the heterozygous state and limb girdle muscular distrophy 2J in the 
homozygous state. These mutations ablate the interaction between titin and obscurin at the 
sarcomeric M-band and have been proposed to cause a gradual decline in sarcomere stability 
(Fukuzawa et al., 2008; Pernigo et al., 2010).  Oddly, no mutations in the Ig1 domain of 
obscurin have been reported so far. Obscurin and titin also interact in the Z-disk, at the Ig58/59 
domains of obscurin and the Z9/Z10 domains of titin. Moreover, the obscurin variant 
p.Arg4344Gln, located in the obscurin Ig58 domain, was identified as the likely cause of 
hypertrophophic cardiomyopathy (HCM) in a Japanese patient (Arimura et al., 2007). This 
mutation weakens the binding of obscurin to titin, thus suggesting that interactions between 
these two proteins are critical for optimal sarcomere stability and muscle contraction.  In a 
competing line of evidence, knock-in mice carrying the p.Arg4344Gln variant develop HCM 
following trans-aortic constriction intervention (Hu et al., 2017, under review).  However these 
studies suggest other molecular mechanisms than ablation of the canonical titin-obscurin 
interaction. More recently, additional OBSCN mutations have been associated with dilated 
cardiomyopathy (Marston et al., 2015). Finally, knockout mice for the OBSCN gene present an 
altered localization of ankyrin B and dystrophin at costameres that is paralleled by increased 
sarcolemmal fragility and reduced ability to complete intense running sessions (Randazzo et al., 
2013). Following heavy exercise, the diaphragm muscle of these mice presented inflammation 
and hyper-contractures with evidence of wavy and less defined M-band and H-zone (Randazzo 
et al., 2017).  Together, these studies present significant circumstantial evidence that obscurin 
mutations are linked to muscular dystrophies. 
In this current study, we propose a new obscurin mutant that is more directly associated 
to dystophies.  However, this study cannot offer a direct link between obscurin and muscular 
dystrophy due to a second gene also being mutated in the human cohort studied by our group.  
This second gene, encoding filamin C (FLNC) is linked to myopathies inherited as a dominant 
trait, which may present with different clinical and histological features (Duff et al., 2011; 
Guergueltcheva et al., 2011; Kley et al., 2012). Patients with FLNC mutation have progressive 
proximal muscle weakness associated with the presence of aggregates of desmin and myotilin, 
among other proteins within myofibers, thus resembling typical profiles of myofibrillar 
myopathy (Kley et al., 2012). Interestingly, a non-myofibrillar myopathy with distal muscle 
involvement has been reported in three related families from Bulgaria carrying a frameshift 
deletion in FLNC (c.5160delC). This mutation was not only detected in all patients of these 
families, but also in some healthy relatives (Guergueltcheva et al., 2011). Thus, the deletion 
appears to result in a loss-of-function mechanism leading to haploinsufficiency with absence of 
protein aggregates. 
Based on the evidence that i) OBSCN ablation results in structural and functional 
alterations of skeletal muscles in mice, ii) mutations in the obscurin binding domain of titin 
domain M10 are causative of TMD and LGMD2J, and iii) mutations in OBSCN have been 
reported in patients with cardiomyopathy, we investigated whether mutations in OBSCN could 
be also involved in skeletal muscle diseases. Our collaborators performed a mutation screening 




band and Z-disk in patients affected by distal muscular dystrophy. This screening identified an 
OBSCN c.13330C>T mutation, resulting in a p.Arg4444Trp substitution in the obscurin Ig59 
domain. This mutation segregates with muscular dystrophy in a French family. Whole exome 
sequencing (WES) of this family by our collaborators identified an additional single base 
deletion in the FLNC gene (c.5161delG) causing a frameshift mutation (p.Gly1722ValfsTer61). 
However, segregation analysis indicated that this FLNC mutation did not completely segregate 
with the disease, as the mutation was also present in one healthy relative. These findings 
resemble the results previously reported by Guergeltcheva and collaborators (Guergueltcheva et 
al., 2011), where a deletion in the FLNC gene (c.5160delC) was observed in individuals with 
muscular dystrophy and also in healthy individuals. WES analysis performed on the DNA from 
four patients, three with the disease and one healthy, from several Bulgarian families in which 
the FLNC c.5160delC was described and did not reveal any additional gene variant shared by 
affected individuals. Based on our collective findings, we propose that the OBSCN 
p.Arg4444Trp variant may increase the penetrance of the FLNC c.5161delG deletion in the 
French family. Accordingly, variants in the OBSCN gene should be considered as potentially 
causative of muscular dystrophy, alone or in association with variants in other myopathy genes. 
 
Materials and Methods 
Patient Data.† Mutation screening was initially performed in families where the affected 
members presented with a clear distal myopathy phenotype transmitted as dominant trait. The 
study was then extended to a cohort of 110 unrelated patients consisting of 11 cases with 
predominantly proximal muscle weakness, respiratory failure and/or cardiomyopathy, 8 cases 
with predominantly proximal myopathy, 26 cases with initial distal muscle involvement 
subsequently progressing to proximal limb weakness, and 65 cases of patients with a clinical 
history of uncharacterized muscular dystrophy/myopathy. In the French family reported here, 
the proband (III:3), a woman issued from non consanguineous parents, and her second son 
(IV:2), had progressive distal lower limb weakness starting at ages 30 and 14, respectively. The 
proband’s father (II:2) had very late-onset walking difficulties, became wheelchair bound at age 
75 and subsequently died from respiratory insufficiency and pneumonia. The paternal 
grandfather (I:1) also became wheelchair-bound at an advanced age. Other family members had 
no neuromuscular history. The proband and her affected son were followed in Neuromuscular 
Unit of Salpêtrière Hospital (Paris, France). Among the four children of the proband, one 
daughter (IV:3) and one son (IV:4), seen at the Neuromuscular Unit at age of 33 and 32, 
respectively, had a normal clinical examination, with no muscle alteration as shown by MRI.  
Ethics committee approval and written informed consent was obtained for all patients. This 
study complies with the ethical standards stated in the 1964 Declaration of Helsinki.  
Mutation Screening and Genotyping.† Mutation screening by conventional Sanger sequencing 
on specific regions of OBSCN was performed in all family members for whom DNA was 
available. In detail, primers were designed using Primer3 software 
(http://frodo.wi.mit.edu/primer3) to amplify OBSCN exon 2 (coding for the Ig1) and exons 50, 
51 and 52 (coding for the Ig58/59 domains), according to sequence NM_052843. Genomic 
DNA was extracted from peripheral blood leucocytes by standard procedures (Kley et al., 
2012). Amplified DNA fragments were directly sequenced using an ABI Prism 310 apparatus 
(Applied Biosystem). Alternatively, Sanger sequencing was performed using DreamTaq™ 
DNA Polymerase (Thermo Scientific) according to standard protocol and PCR products were 




sequenced on an ABI3730xl DNA Analyzer (Applied Biosystems), using the Big-Dye 
Terminator v3.1 kit and analyzed with Sequencher 5.0 software (Gene Codes Corporation). 
DNA mutation numbering was based on cDNA reference sequence (NM_052843), taking 
nucleotide +1 as the A of the ATG translation initiation codon. The mutation nomenclature 
used follows that described at http://www.hgvs.org./mutnomen/. 
Whole Exome Sequencing (WES).† Whole exome sequencing (WES) was performed on patients 
III:3 and IV:2 at ATLAS Biolabs GmbH using SeqCap EZ Human Exome Library v2.0 (Roche 
NimbleGen) for DNA capture. The enriched DNA was sequenced with an Illumina HiSeq 2000 
platform, 2 x 100 bp. Reads were aligned to the human genome reference GRCh37/hg19 with 
Burrows-Wheeler Aligner and duplicate reads were removed with Picard. The Genome 
Analysis Toolkit was used to realign the reads, recalibrate base quality scores and call variants. 
Variants were annotated using wAnnovar and variants with frequency more than 1% in the 
1000 Genomes or Exome Sequencing Project (ESP6500) databases were filtered out. 
Remaining variants present in both III:3 and IV:2 were analyzed. 
 WES on 3 patients and a normal relative from the Bulgarian families (Guergueltcheva et 
al., 2011), was performed at Centro di Ricerca Interdipartimentale per le Biotecnologie 
Innovative (CRIBI), Padova, Italy. DNA libraries for WES were constructed following the 
standard protocol of the Ion AmpliSeq™ Exome RDY Kit (ThermoFisher Scientific). Starting 
from 100 ng of gDNA, a multiplex-PCR with 12 primer pools was performed in order to allow 
the amplification of 24,000 amplicons per pool, covering the exonic regions of the genomes 
(about 58 Mb). 9 µl of 100 pM barcoded libraries were amplified by emulsion PCR using a 
OneTouch2 instrument. Finally, the barcoded samples were loaded into Ion Proton P1 v3 chip 
and sequenced on the Ion Proton instrument using the Ion Proton HiQ Sequencing kit. The 
bioinformatic analysis was performed on the Ion Torrent Server and the Torrent SuiteTM was 
used to base-call and align the reads to the human reference genome (GRCh37/hg19). 
Alignment BAM files, Coverage Analysis statistics and Variant Analysis VCF files were 
produced. By default, the variant calling was performed using the “Germ Line-High 
Stringency” algorithm. 
Generation of GST Expression Vectors and Constructs for in vitro Translation.† Human 
OBSCN cDNA (NM_052843) coding for Ig58/59 was amplified from total RNA extracted from 
human skeletal muscle tissue using specific primers (forward primer: 5’- aagaacacggtggtgcggg 
– 3’; reverse primer: 5’- gaggcccagcagggtgagc-3’). The OBSCN cDNA containing the 
c.13330C>T variant was generated by PCR using primers designed to introduce the cytosine to 
thymine nucleotide change into the wild-type cDNA (forward primer: 5’- 
aacgcggcggtcTgggccggcgcacag – 3’; reverse primer: 5’- ctgtgcgccggcccAgaccgccgcgtt-3’) and 
sequenced using an ABI Prism 310 apparatus (Applied Biosystems). The amplified sequences 
were cloned into the vector pGEX (GE Healthcare) using the EcoRI-SalI sites to generate GST-
OBSCNWT and GST-OBSCNMUT fusion proteins. Human TTN cDNA (NM_001267550) was 
amplified from total RNA extracted from human skeletal muscle tissue using specific primers. 
The TTN cDNA containing the Z9/Z10 domains of TTN was generated by PCR using the 
following primers (forward primer: 5’ - gacaaagagaaacaacagaaa – 3’; reverse primer: 5’ – 
atcttccctctgttgaatctc – 3’) and sequenced using an ABI Prism 310 apparatus (Applied 
Biosystems). The amplified sequences were cloned into the vector pGBK-T7 in frame with a 
myc tag epitope (Clontech) using the EcoRI-SalI sites.  




Protein Expression and in vitro Interaction Studies.† GST fusion proteins grown in Escherichia 
coli (E. coli) (BL21(DE3)) were induced at OD600=0.6 with 1 mM isopropyl β–D-
thiogalactopyranoside (IPTG) for 3 hrs at 30°C. Cells were harvested centrifugation at 4000 xg 
for 10 min at 4°C. The pellet was resuspended in cold buffer containing Phosphate Buffer 
Saline (PBS), 1% Triton X-100, 20 mM EDTA and lysed by sonication on ice. The soluble 
fraction was obtained by centrifugation at 13200 xg for 15 min at 4°C. The fusion proteins were 
immobilized by incubating 1 ml of the soluble fraction with 100 µl of glutathione-Sepharose 4B 
resin (GE Healthcare, Buckinghamshire, United Kingdom) for 10 min and washed three times 
with 1 ml of a buffer containing PBS and 1% Triton X-100 (Rossi et al., 2014a). Beads were 
finally resuspended with an equal volume of PBS and the protein was eluted from the column 
with glutathione-PBS buffer. 
In vitro translation and transcription experiments were performed using the TNT Quick 
Coupled Reticulocyte Lysate System as described by the manufacturer (Promega). 5 µl of the 
translation reaction were incubated with 12 µg of GST fusion protein in a buffer containing 10 
mM Tris-HCl pH 7.9, 150 mM NaCl, 0.5% NONIDET P-40, 1 mM DL-Dithiothreitol (DTT), 1 
mM phenylmethylsulfonyl fluoride (PMSF) and protein inhibitor mixture for 1.5 hrs at 4° C. 
After incubation, the GST fusion protein complexes were washed 3 times with interaction 
buffer. Bound proteins were eluted by boiling in sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) sample buffer and analysed by SDS-PAGE. 
Western Blot Analysis. Protein samples were separated by 10% SDS-PAGE. Filters were 
incubated with primary antibody (mouse anti-c-myc, Clontech-Zymed Laboratories Inc.), and 
diluted in blocking buffer overnight at 4°C with agitation. Filters were washed three times with 
washing buffer (0.5% non-fat dry milk, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.2% Tween-
20) for 10 min each, incubated with horseradish peroxidase-conjugated secondary antibody and 
detected using the ECL system (ECL Western Blot Detection Reagents, Promega). 
Nuclear Magnetic Resonance (NMR) Preparation and Data Collection. All chemicals were 
ACS grade or higher and were typically purchased from Fisher Scientific unless otherwise 
specified. Recombinant 15N, 15N-13C, and unlabeled protein were purified after overexpression 
in BL21 cells using a pET24a vector system (Novagen, San Diego CA) in a manner similar to 
(Rossi et al., 2014b). All nuclear magnetic resonance (NMR) experiments were collected on a 
600 MHz Bruker Avance II spectrometer equipped with a TXI room temperature 5 mm probe 
with z-axis pulse field gradient coils. All NMR samples were collected at 25 C in 20 mM Tris 
pH 7.5, 20 mM NaCl, 0.35 mM NaN3, and 0.5-2.5 mM protein with 10% D2O. All 2D and 3D 
NMR experiments were collected as previously described (Rossi et al., 2014b). Further 
description of NMR collection is located in the supplemental information. Chemical shifts for 
Ig59 have been deposited in the Biological Magnetic Resonance Bank (BMRB) under 
accession number 26593. 
 A 2D HSQC was collected, as well as standard triple resonance experiments including 
HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, C(CO)NH, H(CCCO)NH, 15N-edited 
TOCSY, 15N-edited NOESY, 13C-edited NOESY, and pseudo-3D IPAP experiment for H-N 
residual dipolar couplings, as previously described (Rudloff et al., 2015). Both NOESY 
experiments used 110 ms mixing time. Most experiments were collected with 128, 64 and 1024 
points in the T1, T2, and T3 dimensions, respectively. NMR data were processed with 
NMRPipe (Muntoni, 2007), extended in the indirect dimension via linear prediction, and the 
resulting spectra were analyzed via Sparky (Lee et al., 2015).  
 Standard Bruker IPAP experiments using 256 points for each T1 dimension were used 
to collect RDC data in isotropic and axially-compressed 5.5% acrylamide gel samples, as 




previously described (Ng et al., 2012). The program PALES was used for RDC alignment 
tensor fitting with a calculated Aa and Ar component of 0.00163 and 0.000901, respectively 
(Sewry, 2010). For all experiments, the 1H chemical shifts were referenced to external DSS, the 
13C shifts were referenced indirectly to DSS using the frequency ratio 13C/1H = 0.251449527 
and 15N shifts were referenced indirectly to liquid ammonia using 15N/1H = 0.101329118. 
NMR Structure Calculation. Interproton distance constraints were derived from 3D NOESY 
experiments (15N-edited and 13C-edited 3D NOESY) as described previously. Dihedral 
constraints  ± 20˚ and ψ ± 15˚ for -helix and  ± 40˚ and ψ ± 40˚ for -sheet were included 
based on TALOS+ and the chemical shift index of 1H and 13C atoms (Rudloff et al., 2015). 
Residual dipolar coupling data was included based on splitting values from an IPAP 
experiment, as previously described (Shen et al., 2009). More information about the structure 
calculations can be found in the supplemental information. The final 20 structures were selected 
(from 200) based on lowest Q-values and lowest root mean squared deviation (RMSD) from the 
average, and were of high quality based on the statistical criteria listed in supplemental Table 3. 
The coordinates of the human OBSCN Ig59 structure have been deposited in the Protein Data 
Bank (2N56). 
 An ensemble of structures without dihedral restraints had a backbone RMSD of 0.85 Å 
when compared to structures with dihedral constraints (Udd, 2012). We attempted to further 
verify the structure by performing a H-D exchange experiment, however this Ig domain 
remains unfolded after lyophilization. Therefore, hydrogen bond constraints were not tested 
directly but instead were added into the structure only after the secondary structure was 
completely determined. Structures calculated without hydrogen bonds had an RMSD of 0.59 Å 
when compared to those calculated with hydrogen bonds, indicating that inclusion of these 
bonds did not drastically influence the overall structure. Hydrogen bond constraints of rHN-O = 
1.5 Å to 2.8 Å and rN-O = 2.4 Å to 3.5 Å were included in the final stage of structure 
calculations, and were based off regions that were clearly in well-defined secondary structural 
motifs. Pseudopotentials for secondary 13Cα and 13Cβ chemical shifts and a conformational 
database potential were included in the final simulated annealing structural calculations using 
the computer program XPLOR-NIH (Mastaglia and Laing, 1999; Udd and Griggs, 2001). 
Structures run with and without these pseudopotentials show an RMSD of 0.58 Å. The 
internuclear dipolar coupling (in Hz) were determined from the difference in J splitting between 
isotropic and radially compressed polyacrylamide, and were incorporated into the final 
structure calculation as previously described using an energy constant of 0.50 (Evilä et al., 
2014; Gautel, 2011). A comparison of structures run with and without RDC measurements 
show an RMSD of 0.67 Å. Q-factors were calculated by randomly removing ≈ 10% of the N-
HN RDC data, and then comparing these values to those back-calculated from the structure.  
Purification of Obscurin Ig59. Protein samples of pet-24a(+) human obscurin Ig59 were 
expressed in E. coli and purified through the following procedure. Starter cultures (~5mL) of 
Ig59 were made following addition of glycerol stock (500ul Ig59 PEP24A BL-21 cells into 
50/50 glycerol) and 10ul of kanamycin. Starter cultures were shaken overnight at 37C, 250rpm, 
then added to 1L flasks of Luria broth (LB) (10g tryptone, 5g yeast extract, 5g NaCl, dilute to 
volume with diH2O) along with 1mL kanamycin. These flasks were also shaken at 37C, 
250rpm. Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG. 
Approximately 3hr later, flasks were taken out of the incubator/shakers and centrifuged using a 
JLA 16.250 rotor at 6000rpm, 4°C for 15min. The supernatant and pellet were separated and 
the pellet was kept at -80°C until ready for further purification. Pellets were resuspended in 
G75 buffer (20 mM Trist, 50 mM NaCl, azide) and 100ul PMSF was added to prevent 
degradation during sonication at 100% amplification, 15s pulse, for 30min, then centrifuged 




using a JA 25.50 rotor at 14000rpm, 4°C for 30min. The supernatant was run over a Nickel 
column and the eluent was concentrated in a 5K concentrator tube via centrifugation at 
4500rpm for 90min intervals until less than 1mL solution remained, then run over a size 
exclusion column. Contents of column fractions were visualized using gel electrophoresis; 
fractions containing Ig59 were pooled and concentrated. The concentration of Ig59 in the 
resulting solution was obtained using a Thermo Scientific Nanodrop 2000 Spectrophotometer 
using the extinction coefficient (12490 cm-1M-1) and molecular weight (11.1 kDa) of Ig59. 
Crystallization and X-ray Diffraction. The hanging drop method with 17% tacsimate, 0.1M 
HEPES pH 7.5, 4% 
PEG3350, and 10 mg/mL 
protein was used to obtain 
Ig59 crystals. Crystals were 
harvested and frozen in 
liquid nitrogen after one 
week using a glucose 
cryoprotectant and 
crystallographic reflections 
were collected at the 
Structural Biology Center 
beamline 19-ID-D at the 
Advanced Photon Source, 
Argonne National 
Laboratory. HKL2000 data 
processing calculated the 
unit cell to be P 31 2 1 
(Otwinosky and Minor, 
1997). 
Structure refinement. 
Crystal diffraction phasing 
was determined using the 
program Phaser-MR in the 
PHENIX ver 1.72.2-869 
program suite via molecular 
replacement using PDB and 
reflection files from 
accession numbers 2YZ8 
and 4RSV. The resulting 
structure was refined using 
the program PHENIX ver. 
1.72.2-869-refine (Afonine 
et al., 2012). COOT was 
used to manually rebuild the 
structure in iterative rounds 
of rebuilding and refinement 
in PHENIX refine, resulting 
in a 1.18 Å resolution 
structure with an Rfree value 
of 0.185 (Emsley et al., 
2010). More refinement 
Wavelength (Å) 0.97918 
Resolution range (Å) 30.49 - 1.177 (1.219 - 1.177) 
Space group P 31 2 1 
Unit cell (Å) 60.98 60.98 47.56 90 90 120 
Unit cell (°) 90 90 120 
Total reflections 662701 (35265) 
Unique reflections 33764 (3303) 
Multiplicity 19.5 (10.7) 
Completeness (%) 98.82 (92.53) 
Mean I/sigma(I) 22.98 (5.07) 
Wilson B-factor 14.83 
R-merge 0.1345 (0.5394) 
R-meas 0.1389 
CC1/2 0.988 (0.912) 
CC* 0.997 (0.977) 
R-work 0.1642 (0.2634) 
R-free 0.1851 (0.2974) 
Number of non-hydrogen 
atoms 
775 
 macromolecules 678 
 ligands 0 
 water 97 
Protein residues 90 
RMS(bonds) 0.033 
RMS(angles) 1.46 
Ramachandran favored (%) 99 
Ramachandran outliers (%) 0 
Clashscore 2.23 
Average B-factor 20.5 
 macromolecules 19.4 
 ligands 0 
 solvent 28.3 
Table 2. Final refinement statistics of human obscurin domain Ig59. 




statistics are given in Table 2. The coordinates of Ig59 have been deposited in the PDB under 
accession number 5TZM. 
Molecular Dynamics Modelling. Coordinates corresponding to the crystal structure of Ig59 
were allowed to equilibrate using YASARA 12.7.16, at 310K, 150 mmol/L NaCl, pH 7.4, using 
the Amber ff03 forcefield in a simulation cell with periodic boundaries until the backbone 
RMSD no longer changed significantly (Wright et al., 2005). Simulations were run with a 
timestep of 1.25 fs with the temperature adjusted using a Berendsen thermostat as described by 
Krieger et al. (Krieger et al., 2014; Kireger et al., 2004). Once finished, the p.Arg4444Trp 
mutation was introduced to the simulation using the ‘swap’ function in YASARA. This mutated 
structure was then once again allowed to equilibrate using the same parameters as for the wild-
type structure, and the simulation was terminated when the RMSD stabilized. YASARA and 
Pymol were used to visualize the structures (de Groot et al., 1997; The PyMOL Molecular 
Graphics System). 
Circular Dichroism. All CD experiments were conducted in a 1 mm pathlength cuvette at 15 
μM protein in 20 mM Tris buffer, pH 7.5 and 100 mM NaCl. Samples were measured in 
triplicate at 37°C on a Jasco J-810 spectrophotometer. 
 
Results 
Clinical Findings. † Our collaborators performed quantitative studies on human patients with 
dystrophies in order to investigate the disease. The proband (III:3) of these studies was a 61-
year-old female presenting a progressive distal dystrophy since around age 30, affecting 
successively the right hand and progressing slowly to include both distal upper and lower limbs. 
At age 45, difficulties in standing up from a chair and a steppage gait appeared. At age 51, 
ambulation was not limited, but the patient exhibited foot drop (more pronounced on the right 
side), inabilities to stand on tip toes or heels, and a waddling gait. Hand finger extensors, foot 
evertors, toe extensors, and calf muscles showed severe weakness, but finger flexors and the 
tibialis anterior were normal. Glutei maximi, thigh adductors, and hamstrings were also 
severely affected, but proximal scapular, brachial, and antebrachial involvement was not 
detected. Hand palmar muscles (mainly thenar ones), calves and tibial muscles were atrophic 
(Fig. 1A1-5). In addition to the worsening myopathy, a progressive cervical myelitis of 
unknown aetiology appeared at age 52, manifesting as a sensory defect mainly in left lower 
limbs and spreading from foot to hip, causing severe pains and impaired balance. At age 61, she 
could walk slowly a few hundred meters with two aids. The previously described clinical 
selective pattern was found with severe wasting of hand finger extensors, toes extensors, 
peroneus lateralis, posterior calf muscles, and hamstrings. Hand finger flexors, tibialis anterior, 
quadriceps, along with scapular, brachial, antebrachial, axial, facial and oculo-bulbar muscles 
remained mostly spared. Quantitative measurements are detailed in Table 3. A sensory defect 
due to the myelopathy was found in both distal and proximal lower limbs (left > right). Creatine 
kinase (CK) levels were normal. Electromyogram (EMG) showed myopathic changes distally 
in the upper limbs and both proximally and distally in the lower limbs. Cardiac evaluation 
(ECG and echocardiography) and spirometry were normal. Spinal cord MRI performed at age 
53 revealed a posterior hyperdense signal from C2 to C7 (Fig. 1-C2-C7). Brain MRI and CSF 
were normal.  




 Our collaborators reported that the proband’s son (IV:2) noticed first symptoms 
(fatigability in walking and difficulties in standing on tip toe) at age 14. He has been unable to 
run since the age of 16 years. He could walk a distance of around 1000 meters without aid at 
age 33. He had marked weakness and atrophy in the calf muscles and minor weakness in the 
interossei and finger extensors, but otherwise normal muscle strength in the proximal lower 
limbs and in the upper limbs (Table 3). No facial or bulbar weakness was present. CK levels, 





Table 3. Quantitative clinical measurements performed by our collaborators documenting the progressive muscular dystrophy of the proband and her son. 
Case 
Age  
Sex    
Symptom 
onset 
(age in years)  
Course 
  




Muscle weakness   
Current status 
Muscle atrophy   
CPK/ EMG / Cardiac 













(≈ 30y)    
Progressive worsening  
Around 30y :  both hands 
wasting, inability to stand on 
heels and tiptoes,           35 y 
difficulties climbing stairs. 
46 y Gowers, difficulties standing 
from a chair, running inability. 
Increased weakness of foot 
evertors, hand finger extensors 
52y : cervical myelitis 
manifesting by  left foot 
extending to whole limb after 6 
months.  sensory defect  without 
identified cause (Spine MRI T2 
sequence hypersignal from C2 to 
C7) 
(normal Brain MRI, normal CSF  
fluid) 
Increased loss of balance and 
cordonnal pains 
53 y : fallings (weakness and 
balance impairment) 
59 y :  walk with  bilateral aid  
(61y)                                      
Walking distance : few  
hundreds meters with  aid 
Fallings, four to five 
times monthly 
right foot elevator  
Difficult walk with 
steppage and tendency to 
internal rotation of feet 
10 m in 15 s with a cane.  
Inability to stand on heels 
and tiptoes 
Rising from chair 9 times 
in 60 s with two hands 
Thigh crossing  : difficult 
 
Arm elevation : normal 
  
Painful spinal posterior 
column syndrome 
(myelitis) 
Lower limbs  
Toes extensors  2, except big toe, 
1 , Peroneus 1, , Tibialis anterior  
4,    Post legs  2+ Hamstrings  2, 
Quadriceps 5- 
Adductors  2+, Glutei maximi  
2+,  Glutei medii 4+, Iliopsoas 4+ 
Upper limbs  
Finger extensors 3-,  index  more 
affected :                                            
right    index 2, left 2+ 
Finger flexors  4+ 
wrist extensors 4 
scapular and brachial 5  
Axial and neck  
flexors 4-               
facial, oculobulbar normal  
 
in addition : hypoesthesia of 





Hand : palmar, 
mostly  thenar 
region 
CK  normal 
 
EMG :  myogenic 
Distal in Lower limbs, Distal + 
proximal in lower limbs  
Nerve : normal   
No decrement 
 
Normal echography and EKG 
 
VC  : 85%   
Case II 
Son of 











Mild progression  
At 16 y, interruption of sport at 
school and inability to run.    
(33y)  
Walking distance  : 1000 
m without aid 
No fallings 
Climbing stairs with 
banister  10 m : 12s 
Rising from a chair : 24 
times in 60 s  without aid  
Arm elevation : normal  
 
Lower limbs  
Peroneus 3-, Tibialis anterior 3+   
Toes extensors between  4 , and 2 
(big toe)  Post legs 2   
Pelvic and femoral muscles 5 
Upper limbs  
Finger extensors 4+,                                                     
    Finger flexors 5  
wrist extensors 5 
scapular and brachial 5  
Axial and neck  
flexors 5              




No atrophy of 
upper limbs 
CK  normal 
EMG :  diffuse  myogenic 
pattern 
Nerve : normal 
Normal echography and EKG 





 Muscle imaging performed by our collaborators on the mother at the age of 51 showed 
severe fatty degenerative changes in almost all lower leg muscles, except for tibialis anterior, 
posterior and long toe flexor muscles. The quadriceps was considerably less affected than the 
hamstrings and adductors. Glutei maximi and iliopsoas were less affected than glutei minimi and 
medii. The forearm extensor 
muscles showed reduced volume. 
At age of 61 years, this pattern 
remained mostly unchanged, 
except that the vastus medialis and 
vastus internalis fatty degeneration 
was more marked, particularly in 
right side. Rectus femoris and 
vastus lateralis remained spared 
(Fig. 1). In the 33-year-old son, the 
changes in CT scan were milder, 
with the exception of severe fatty 
replacement in the calf muscles 
and, less severely, in the lateral 
compartment peroneal muscles. All 
other muscles were intact.  
 The radialis muscle biopsy 
from the proband (III:3) performed 
at 51 years showed some nuclear 
internalization, fiber size variation 
(Fig. 1B1), and type 1 
predominance. Oxidative 
histoenzymatic reactions disclosed 
few lobulated fibers and uneven 
staining of the intermyofibrillar 
network (Fig. 1-B2). Our 
collaborators’ peroneal muscle 
biopsy of the son (IV:2) at 33 years 
showed marked fiber size 
variability with the presence of 
some atrophic angulated fibers (Fig. 
1C1). A few lobulated fibers were 
also present. 
Immunohistochemistry performed 
in both muscle biopsies revealed 
some desmin surcharge in both 
patients (Fig. 1B3, C2). In contrast 
only patient IV:2 (the son of the 
proband) harboured alphaB 
crystallin immunoreactive 
aggregates (Fig. 1C4). Myotilin 
immunostaining did not show 
Figure 1. A/B) Clinical data, C) morphological studies, and 
D) ultrastructutal studies of the proband (III:3). A1-3: 
Evidence of muscle atrophy in thenar muscles. A4-5: All 
distal leg muscles of the proband are markedly affected, 
except for tibialis muscles. B1-4: Computed Tomography 
(CT) of the proband at the age of 51 showed severe fatty 
degeneration changes in most leg muscles. C1-C4: Radialis 
muscle biopsy of proband (III:3). C1. Haematoxylin & Eosin: 
presence of some nuclear internalization and fiber size 
variation. C2 NADH: lobulated fibers are indicated by an 
arrow; uneven staining of the intermyofibrillar network in 
some fibers is indicated by a star. C3 desmin: mild diffuse 
desmin surcharge in several fibers C4 myotilin.:ormal 
staining. C5-C8: Peroneal muscle biopsy from the proband 
son (IV:2). C5 NADH: atrophic lobulated fibers are indicated 
by an arrow. C6 desmin: mild diffuse desmin surcharge in 
several fibers. C7 alpha B cristallin: presence of dense 
protein aggregates. C4 myotilin: normal staining. D. Radialis 
muscle biopsy of proband (III:3), EM analysis. D1: presence 
of numerous abnormal mitochondria harbouring dotty or 
paracrystallin inclusions, in proximity of the star. D2: 
presence of a cytoplasmic protein aggregate composed by 
dark osmiophilic granulo-filamentous material corresponding 
to desmin, indicated by an arrow, and filamentous material 




specific alterations (Fig. 1B4, C4). Ultrastructural studies performed by our collaborators on the 
proband (III:3) showed myofibrillar disorganizations resembling targetoid structures in a small 
percentage of the fibers (not shown). Abnormal mitochondria with some paracristalline 
inclusions (Fig. 1B5, indicated by a star) and dark dots were observed in numerous fibers. Focal 
disintegration of myofibrils, dark osmiophilic granulo-filamentous material corresponding to 
desmin (Fig. 1C5, indicated by an arrow) and filamentous protein aggregates (Fig. 1C5, 




performed by our 
collaborators 
using the DNA 





mutation in the 
FLNC gene 
(NM_001458.4). 
This was a 
deletion of a 
single base in 
exon 30 
(c.5161delG) 
resulting in a 




Ter61, Fig. 2B). 
Sanger 
sequencing for 




II:1, III:3, III:4, 
IV:1, IV:2 and 
IV:3. The FLNC 
variant 
c.5161delG was 
present in the 
two affected individuals (III:3, IV:2) but also in one healthy individual (IV:3). This deletion is 
located adjacent to the previously reported c.5160delC deletion, which is linked to distal 
Figure 2. Genetic analysis of OBSCN c.13330 C>T and FLNC c.5161delG 
mutations. A) Family pedigree. Black filled symbols represent affected family 
members. The genotype of individuals is shown as follows: +/+ wild type, OBSCN 
+/- heterozygous for the c.13330 C>T mutation, FLNC +/- heterozygous for the 
c.5161delG mutation. Arrow indicates the proband. B) Electropherogram of the 
OBSCN gene sequence (upper panel) and of the FLNC gene sequence (lower 
panel). C) Phylogenetic alignment of the OBSCN orthologs. Sequences 
represent the Ig59 domains of OBSCN in distinct mammalian species. The 
arginine in position 4444 in the human OBSCN sequence is highlighted in yellow 
and is conserved in mammalian species. D) Interaction between titin domains 
Z9/Z10 and OBSCN domains Ig58/Ig59. in vitro transcribed and translated myc-
tagged titin domains Z9/Z10 were used in pull-down experiments with GST-fusion 
proteins containing either wild type OBSCN Ig58/Ig59 domains (OBSCNWT) or 
R4444W mutated OBSCN Ig58/Ig59 domains (OBSCNMUT). Proteins were 
separated by SDS-PAGE, transferred to membranes and detected by mouse 
anti-myc antibodies. E) Quantification of GST pull-down efficiency. Protein bands 
intensities of myc-tagged Z9/Z10 titin domains precipitated by either OBSCNWT or 
OBSCNMUT GST-fusion proteins were evaluated by densitometric analysis and 
normalized on GST fusion proteins content. Data represent means values ± 
standard deviation of five independent experiments in triplicate. * p < 0.01 




myopathy with upper limb predominance in three Bulgarian families (Guergueltcheva et al., 
2011). To investigate if the OBSCN variant identified in the French family was present also in 
the Bulgarian families with recurrence of the FLNC c.5160delC frameshift, our collaborators 
initially performed Sanger sequencing of exons 2, 50, 51 and 52 of the OBSCN gene in 12 
individuals from the three related Bulgarian families [3 unaffected non-carriers of the FLNC 
c.5160delC (2701:IV.1, 2702:III.3; 2703:IV.3), 4 asymptomatic carriers of the FLNC c.5160delC 
(2701:IV16; 2701:V1; 2701:V2; 2702:IV3), and 5 individuals with distal dystrophy carrying the 
FLNC c.5160delC(2701:IV3; 2701:IV.10; 2702:III.1; 2702:IV.1; 2703:III.2)]. Since this initial 
screening did not identify any variant in the selected exons of OBSCN, WES analysis was 
performed by our collaborators in three affected FLNC mutation carriers and one normal relative 
from the Bulgarian families (patients IV:3 of family 1, III:1 of family 2, III:2 of family 3 and 
individual IV:1 of family 1) Variants were filtered for a global minor allele frequency ≤0.001, 
shared by the affected individuals but not present in the asymptomatic member. This analysis 
identified no mutation (missense, nonsense, indel) shared by the patients and not present in the 
normal relative of the Bulgarian families.  
Structural Studies of the Ig59 Domain of OBSCN. From the above analysis, we reasoned that the 
dual OBSCN and FLNC mutations may represent a digenic heterozygous condition, where the 
OBSCN mutation leads to an increased penetrance of the FLNC mutation. In order to begin 
defining the molecular mechanism of the described phenotype, we investigated how the normal 
and mutated obscurin Ig59 domain interacts with its binding partner titin. We first solved the 
high-resolution structure of Ig59 (residues 4428-4521). Human obscurin Ig59 was isolated based 
on the original sequence alignment (CAC44768.1) (Young et al., 2001). After purification, the 
beta-sheet rich structure was verified by CD, the pure Ig59 was crystallized. The resulting 
crystals diffracted to a resolution of 1.18 Å (Fig. 3A, Table 2). The resulting structure shows beta 
sheets extending from Glu 4435 to Lys 4438 (strand A’), Ala 4440 to Arg 4443 (strand A), Ala 
4446 to Thr 4453 (strand B), Ser 4464 to Ile 4468 (strand C), Trp 4479 to Asp 4484 (stand D), 
His 4487 to 
Leu 4493 
(strand E), 
















Figure 3: Structure and analysis of human obscurin Ig59. A) Cartoon of the Ig59 crystal 
structure, showing the typical Ig-like fold. B) Comparison between the Ig59 NMR and X-
ray structure. C) CD plot of WT obscurin Ig58-59 (black squares) and p.Arg4444Trp 
(open circles). D) MD simulated average models of WT (blue) and Arg4444Trp (red) Cα 
positions. The side chains for Arg4444/Trp4444 are shown. E) RMSD vs residue 
number comparison of the mutant model to the wild-type model. The Arg444Trp site is 




An independently solved NMR solution structure of human obscurin Ig59 contains 
greater than 12 restraints per residue (Fig. 3B, Fig. 4, Table 4). The overall backbone root mean 
squared deviation (RMSD) of ordered heavy atoms is 0.609 Å. With the exception of Arg 4430, 
and Arg 4508, every backbone H-N bond and most sidechain C-H shifts are visible in these 
NMR experiments. H-N residual dipolar coupling experiment values independently verify the 
validity of this 
structure, and result 
in a Q-factor of 0.25 
±0.02. The NMR 
and X-ray structure 
have a pairwise 
RMSD of 1.609 Å 
(Fig. 3B). The 
differences between 




Asn 4468 and Ser 
4478. This area is in 
a long loop region, 
and is associated 
with higher B-
factors in the X-ray 
structure and a 
lower number of 
NOE restraints in 
the NMR structures. 
Aside from this 
area, the structures 











Figure 4. NMR data used to determine the structure of human obscurin Ig59.  
A) Observed beta sheet interactions of Ig59 as seen in the 15N-edited NOESY. 
B) NOESY data (in black) overlaid with TOCSY data (in red), showing self-
peaks and cross-strand NOEs. C) Example of CBCA(CO)NH (in red) and 
HNCACB (in black) experiments, showing NMR assignments. D) Example of 
residual dipolar coupling data showing isotropic (right) and anisotropic (left) 




Table 4. NMR-derived statistics of 20 NMR structures1 of human obscurin  
domain Ig59. Parenthesis indicate the number of restraints. 
 The 
p.Arg4444Trp mutation 
could affect the obscurin-
titin interaction in two 
ways: it may unfold the 
entire Ig59 domain, or it 
may maintain the fold 
and simply perturb the 
binding event. To 
examine the effect of the 
p.Arg4444Trp mutation 
on the Ig59 structure, we 
conducted circular 
dichroism (CD) 
experiments on the WT 
and mutant forms of Ig59. 
As can be seen in Fig. 
3C, the CD profiles are 
virtually identical, 
suggesting that the 
mutation does not 
globally disrupt the 
overall Ig-like 
architecture. To gain 
greater insight into the 
local effect of the 
p.Arg4444Trp, the WT 
and mutant protein 
structures were examined 
using molecular 
dynamics (MD). In each 
case, the RMSD relative 
to the starting model was 
measured until the 
simulation was fully 
equilibrated. The resulting models of wild-type and p.Arg4444Trp were then compared (Fig. 3D, 
E). While the long flexible loop between residues 4468 and 4478 was significantly different 
between these simulations, regions around the mutation were virtually unchanged in structure. 
Thus, these in silico results are consistent with our CD work showing that the mutation does not 
change the Ig59 structure significantly. Therefore, the p.Arg4444Trp variant likely directly alters 
the obscurin-titin interface. 
1 The 20 ensemble structures, <20>, are the results of simulated annealing calculations. The best 
structure is the closest to the average structure. The values shown for the <20> are the mean ± 
standard deviation. 
 <20> Best 
RMSD from distance 
constraints (Å)2 
  
 total (1061) 0.028 ± 0.002 0.029 
 intraresidue (228) 0.005 ± 0.004  0.003 
 sequential ( |i – j| = 1)  (382) 0.019 ± 0.005  0.022 
 medium range ( 1 < |i – j| ≤ 
1)  (95) 
0.046 ± 0.006 0.056 
 long range ( |i – j| = 1)  (292) 0.031 ± 0.003 0.003 
 hydrogen bonds  (64) 0.056 ± 0.006  0.050 
RMSD from exptl dihedral 
constraints (°) 
  
 Φ,Ψ  (144) 0.687 ± 0.116  0.684 
RMSD from dipolar 
coupling restraints (Hz) 
  
 DNH  (52) 0.89 ± 0.09 0.93 
RMSD from exptl 13C 
chemical shifts 
  
 13Ca (ppm) 1.59 ± 0.17 1.31 
 13Cb (ppm) 1.46 ± 0.04 1.47 
RMSD from idealized 
geometry 
  
 bonds (Å) 0.004 ± 0.001 0.004 
 angles  (°) 0.633 ± 0.020  0.640 
 impropers  (°) 0.442 ± 0.036  0.431 
Lennard-Jones potential 
energy (kcal/mol)3 
-363 ± 10 -359 
Q-value4 0.27 ± 0.04 0.25 
% most favorable region in 
the Ramachandran plot5 
74.1± 3.0 72.8 
RMSD of the mean 
structure (Å)6 
  
 all backbone atoms (3-91) 0.609 ± 0.063  0.494 




2 None of the 20 structures has a distance violation > 0.35 Å or a dihedral angle violation of > 5°. 
The force constants used in the SA calculations are as follows: 1000 kcal mol −1 Å2 for bond 
length, 500 kcal mol−1 rad−2 for angles and improper torsions, 4 kcal mol−1 Å−4 for the quartic van 
der Waals (vdw) repulsion term (hard-sphere effective vdw set to 0.8 times their values in 
CHARMm parameters), 50 kcal mole−1 Å−2 for experimental distance constraints, 1 kcal mol−1 Å−2 
for distance symmetry constraints, 0.5 kcal mol−1 ppm−2 for the 13C chemical shift constraints, 
and 1.0 for the conformational database potential. The force constants (in kcal Hz−2) used for 
dipolar coupling restraints is 0.50. 
3 Lennard-Jones van der Waals energies were calculated using CHARMm parameters and were not 
used in any stage of the structure determination 
4 Q-values were determined by randomly removing 10% of all RDC values. To ensure accuracy, an 
ensemble of structures with a second randomly removed subset of RDCs was also run. The Q-value 
of this second set was similar to the first. 
5 PROCHECK was utilized to generate the Ramachandran plot 
6 Backbone calculations include Cα, N, and C′ atoms. Only residues 3–91 are included since no 
long-range NOE correlations were observed for residues 1–2 and 92–104. 
 
The p.Arg4444Trp Variant Reduces the Interaction between Obscurin Ig58/59 and Titin Z9/Z10 
Domains. To directly evaluate whether the p.Arg4444Trp variant alters the interaction of the 
Ig58/59 domains of obscurin with the Z9/Z10 domains of titin, we performed GST-pull down 
assays with either immobilized GST-obscurinWT or GST-obscurinMUT mixed with in vitro-
translated titin Z9/Z10, cloned in frame with a myc-tag epitope. Densitometric quantification of 
the binding between the Z9/Z10 domains of titin and the Ig58/59 domains of obscurin showed 
that the bound fraction of GST-obscurinWT protein was approximately two-fold higher than that 
of the GST-obscurinMUT, indicating that the p.Arg4444Trp variant significantly weakens the 
titin-obscurin interaction (Fig. 2D, 2E). Other groups have suggested that this titin-obscurin 
interaction helps to strengthen the Z-line (Bang et al., 2001). Our results show that the 
p.Arg4444Trp variant leads to a partial ablation of titin binding. This event leads to a weaker, 
less organized cytoskeleton, which in turn contributes to the distal muscular dystrophy 
phenotype of affected patients. This general mechanism of action is similar to the titin M10 




 Based on the evidence that the M10 domain of titin is mutated in patients with TMD and 
LGMD2J and that this domain interacts with the Ig1 domain of obscurin (Fukuzawa et al., 2008; 
Pernigo et al., 2010), we hypothesized with our collaborators that the OBSCN gene could 
represent a potential candidate for those cases of muscular dystrophies where a causative gene 
had not been identified. Screening performed by our collaborators of families with undetermined 
distal myopathy led to the identification of a novel variant in OBSCN, p.Arg4444Trp, which co-
segregated with a c.5161delG in FLNC, in two individuals of a French family affected by distal 
muscular dystrophy. The OBSCN p.Arg4444Trp variant is conserved across mammalian species 
and is localized in a region of the protein that mediates the binding to the Z9/Z10 Ig domains of 
titin which facilitates the localization of obscurin to the Z disk region of the sarcomere (Young et 




 Our structural studies showed that the previously mentioned variant does not lead to a 
global Ig59 domain misfolding but instead changes the surface topology of the domain. This 
mutation may thus affect obscurin binding to other members of the myofibril cytoskeleton. Pull-
down experiments showed that this variant specifically weakens the binding between obscurin 
and titin, which may contribute to altered sarcomere stability and, eventually, disease. In support 
of this hypothesis, other mutations have been identified in patients with muscular dystrophies 
that affect the titin-obscurin interaction. For instance, mutations in the titin M10 domain, which 
mediates interaction with the Ig1 domain of obscurin at the M-band, were found to reduce the 
affinity of titin for obscurin and cause gradual failure of sarcomere maintenance in muscles of 
patients affected by TMD and LGMD2J (Fukuzawa et al., 2008; Pernigo et al., 2010). Similarly, 
the p.Arg4344Gln variant located in the Ig58 domain of obscurin identified in a patient affected 
by hypertrophic cardiomyopathy, was found to impair the binding of obscurin to the Z9/Z10 Ig 
domains of titin (Arimura et al., 2007). Moreover, knock-in mice for the p.Arg4344Gln variant, 
when exposed to stress via trans-aortic constriction, develop a severe cardiac hypertrophy within 
4-8 weeks (Hu et al., 2016), further emphasizing the complementary roles of titin and obscurin in 
maintenance of sarcomere stability. 
Interestingly, the two variants of Ig58 and Ig59 mentioned in this text, p.Arg4444Trp of 
Ig59 and p.Arg4344Gln of Ig58, involve a single point mutation from a charged to an uncharged 
residue (Arimura et al., 2007; Fukuzawa et al., 2008; Guergueltcheva et al., 2011; Pernigo et al., 
2010).  The isoelectric points of these regions are approximately 6.34 and 4.16, respectively. 
However, the point mutations cause a shift in isoelectric point to 4.48 and 3.90, respectively. 
Therefore, we hypothesize that the binding events between Ig58/59 of obscurin and Z9/10 of titin 
is electrostatically driven and that the difference pIs account for the reduction in binding affinity 
observed in the variants. In the future, we will test this hypothesis by creating a titin column and 
testing its affinity for the obscurin wild types and variants. If a lower concentration of salt is 
required to wash off the variant compared to the wild type, then we can effectively conclude that 
the variant affinity is lowered due to a decrease in electrostatic interactions. 
 FLNC mutations are known to cause adult-onset distal muscular dystrophy (Kley et al., 
2012; Vorgerd et al., 2005; Shatunov et al., 2009; Luan et al., 2010). The protein product of 
FLNC, filamin C, is an actin cross-linking protein involved in cytoskeleton organization and 
signalling (Razinia et al., 2012). Mutations in FLNC were reported to destabilize muscle tissue 
homeostasis via the formation of protein aggregates (Löwe et al., 2007). In addition, mutations in 
FLNC have been detected in patients with myofibrillar myopathy and also in patients with hand 
muscular dystrophy without myofibrillar aggregates (Duff et al., 2011; Guergueltcheva et al., 
2011).  
 Our collaborators’ clinical evaluations of the proband carrying both the OBSCN 
p.Arg4444Trp variant and the FLNC deletion indicate a late-onset dominant distal muscle 
dystrophy as well as the involvement of additional muscle groups than the Udd Myopathy (Duff 
et al., 2011; Guergueltcheva et al., 2011). The FLNC mutation did not completely segregate with 
the disease, as it was present in the two affected patients as well as one healthy individual in the 
French family analyzed. This incomplete segregation matches the behavior of a similar FLNC 
deletion reported in Bulgarian families (Guergueltcheva et al., 2011), indicating an incomplete 
penetrance of the genotype. WES of representative individuals in the Bulgarian families did not 
reveal the presence of any other gene variants shared by all patients. Thus, the genetics behind 




therefore, needs further analysis. In the French family reported by our collaborators, the 
combination of the FLNC c.5161delG frameshift and the OBSCN c.13330C>T variant co-
segregated with the disease, with the OBSCN variant present only in the affected individuals. The 
healthy relative presenting only the FLNC c.5161delG deletion can be regarded as partial 
asymptomatic carrier.  
 In conclusion, the data on the French family reported by our collaborators depicts a novel 
digenic heterozygosity condition in the genetics of distal dystrophy, resulting in a dominant 
phenotype with quite severe clinical features; individual III:3 was unable to walk and constricted 
to a wheelchair, and IV:2 was unable to run since the age of 16. This phenotype is caused 
partially by an altered titin-obscurin interaction, and partially by altered filament C function of 





Studies on the Molecular Motion, Structure, and Elasticity of Titin 
 
Introduction 
 Titin’s ability to both stretch and recoil is fundamental in preventing muscle 
overstretching and helps myocytes return to their original length. Recent studies have examined 
titin’s mechanosensing abilities using tandem Ig and Fn-III-like domains (Granzier and Labiet, 
2004; Linke et al., 2008; von Castelmur et al., 2008; Lee et al., 2010; Pernigo et al., 2010; Hsin 
et al., 2011). While many of these domains are closely associated with other parts of the 
cytoskeleton, there are ~100 tandem domains in the sarcomeric I-band that are relatively free 
from extensive target protein interactions (reviewed in Kontrogianni-Konstantopoulos et al., 
2009). Improta et al. (1998) and von Castelmur et al. (2008) have shown that this I-band region 
acts as a modified entropic spring whereby each domain behaves as a link in a chain connected 
by 3-5 residue interdomain linker ‘hinges’ (Improta et al., 1998; von Castelmur et al., 2008) 
(Fig. 1).  
 The further a 
polypeptide is stretched, 
the more energy 
additional stretching 
requires (Linke, 2000 
(1);Linke, 2000 (2)). 
Through extensive 
molecular dynamics 
(MD) simulations, Lee et 
al. took this idea further 
and developed a 
comprehensive 
mathematical model 
where tandem Ig domains 
behave as a kind of 
entropic-enthalpic spring, 
termed the ‘modified 
worm-like model’ 
(mWLM) (Lee et al., 
2007; Hsin et al., 2011). In this model, the Ig domains can move stochastically relative to one 
another, though there is also some breaking and forming of transient domain-domain and 
domain-linker non-covalent bonds. The mWLM agrees extremely well with the experimental 
data and explains titin’s stretch resistance at very low forces (1-5 pN) (Linke, 2000 (1); Ma and 
Wang, 2003; Hsin et al., 2011). At slightly higher forces (~5 pN), the mainly disordered PEVK, 
N2A, and N2B regions of titin straighten out in an entropic-enthalpic spring mechanism 
(Frieburg et al., 2000; Bang et al., 2001; Ma and Wang, 2001; Ma and Wang, 2003; Li et al., 
2002; Lee et al., 2007). At extremely high forces (>50 pN), discrete titin Ig and Fn-III domains 
completely unfold, although the physiological relevance of such an event is uncertain (Rief et al., 
2000; Li et al., 2003; Garcia et al., 2009; Stacklies et al., 2009; Lee et al., 2010; Hsin et al., 





2011). Thus, titin displays a continuum of soft elasticity with the application of force (Hsin et al., 
2011). 
 This nuanced view of titin’s flexibility at low forces runs somewhat counter to the crystal 
structure of 6 tandem titin domains, I65-70 (I6), which depict well-formed interactions between 
the linker regions and Ig domains (von Castelmur et al., 2008). Such fixed interdomain 
interactions lead to the ‘carpenter’s ruler’ model. This model reconciles several incongruences 
that arise from thinking of titin as a worm-like model: data collected by cryo-EM show large 
segments of the I-band region to be in straight lines with only occasional bend points, and SAXS 
data indicate a mostly elongated structure (Marino et al., 2006; Vazina et al., 2006; von 
Castelmur et al., 2008; Marchetti et al., 2011). Additionally, the persistence length of the titin I-
band region is longer than a worm-like model would suggest (Di Cola et al., 2005; von 
Castelmur et al., 2008). 
 In an attempt to resolve the discrepancy between the worm-like and ‘carpenter’s ruler’ 
models, we re-analyzed the published crystal structure data (von Castelmur et al., 2008; Lee et 
al., 2007). Many of the linker/domain interactions that are present in the original model and 
contribute to an elongated overall structure are either absent or ambiguous in our structure (Fig. 
1). Examination of symmetry mates suggest that the extended conformation of titin is not based 
on stabilizing domain-linker interactions but based instead on crystal packing interactions. 
 Molecular dynamics simulations performed by others and ourselves support the theory 
that this region of titin can be elongated, however the energy difference between a slightly bent 
and a straight molecule are below the threshold of thermal noise (Lee et al., 2010). Together, 
these X-ray and MD analyses structurally validate the mWLM. Titin likely forms transient 
interdomain interactions, which explains the protein’s resistance to stretch and its persistence 
length. These interactions, combined with limited flexibility due to steric hindrance between Ig 
domains, serve to keep titin in a mostly elongated orientation. While there is computational and 
circumstantial evidence for stabilizing interdomain interactions (Matsubara and Maruyama, 
1977), their presence in this crystal structure is not definite. 
 
Materials and Methods 
 Structure Refinement. PDB and reflection files from accession numbers 3B43 and 2RIK 
were implemented in experimentation. The structure of 3B43 was refined computationally and 
manually using PHENIX ver 1.72.2-869 and Coot was used for iterative rounds of structure 
rebuilding and refinement in PHENIX refine (Terwilliger et al., 2008). Amino acids with 
continuous, clearly defined electron density at 𝜎 ≥ 1.5 for at least two residues were included; 
all others were excluded. Ramachandran outliers were identified using the Molprobity server and 
Coot. Once identified, outliers were corrected. Refinement statistics are given in Table 1 (Chen 
et al., 2010; Emsley et al., 2010). The 2RIK structure was used for investigation of crystal 







Table 1. I6 statistics after refinement. Methods for data collection of I6 are found 






with the PMEMD 
module of the 
Amber 12 MD 
software package, 
the AMBER 12SB 
force field, and a 
generalized Born 
implicit solvent 
(Hornak et al., 
2006; Case et al., 




were set at 100 Å 
for MD and 150 Å 
for steered molecular dynamics (SMD). For equilibrium simulations, constant temperature (T = 
300K) was enforced using a Langevin thermostat with a collision frequency of 1 ps-1. The 
integration time step was 2 fs and all covalent bonds to hydrogen were held fixed with the 
SHAKE algorithm.  
 Steered Molecular Dynamics Simulations. SMD simulations fixed the α-carbon at the N-
terminus of Ig65 (A1) and applied force to the α-carbon at the C-terminus of Ig70 (Q567), 
moving it closer to the N-terminus (Israleqitz et al., 2001). In this way the protein was 




 The original structure of I65-I70 is hook-shaped; the first two domains are oriented 114 
degrees relative to the final four domains, which are nearly linear (von Castelmur et al., 2008). 
The high B factors of the published structure prompted our re-analysis of the electron density in 
3B43 to determine if the sections with high B-factors had well-defined electron density. A 1.5 σ 
cutoff was used to fit the model in Coot. Continuous, unambiguous density for the backbone and 
side chains was required; all other residues and side chains were removed (Table 1 for fitting 
statistics and Fig. 2A). This newly refined structure has an RMSD of 0.6 Å compared to the 
original with several important differences. The overall B-factor is significantly lower than the 
original structure (88.4 Å3 vs 118.5 Å3; Fig. 2A inset). Furthermore, domain Ig68 is almost 
completely absent. In our model, interactions between the Ig domains and linker residues, which 
Resolution range (Å) 16.99-3.30 
Spacegroup P6522 
Unit cell dimensions a=b=141.43Å, c=166.01Å 
α=β=90°, γ=120° 
Solvent content (%) 67.1 
Matthews coefficient 3.74 
Completeness (%) 98.6 
Refinement:  
  No. of reflections 14953 
  No. of protein atoms in asymmetric unit 3371 
  R factor/R free (%) 28.4/31.0 
  RMSD bond length (Å) .0084 
  RMSD bond angle (°) 1.992 
  Avg B factor (B factor range) (Å3) 88.5 (19.9-200.2) 
  Wilson B factor (Å3) 82.6 
  Ramachandran favored (%) 90.6 




were previously postulated to stabilize the structure in an elongated form, are either poorly 
defined or absent (Fig. 2B). These residues were removed due to poor electron density (see 
Materials and Methods for details). Analysis of the entire structure reveals a positive correlation 
between extensive crystal packing interactions and low B-factors (Fig. 2A and C; Fig. 3). 
 From this 
analysis, we 
reasoned that the 
overall shape of this 
region of titin could 
be explained by 
crystal packing 
interactions and not 
through inter-
protein interactions 
(Fig. 2D). Since 














previously solved at 
1.6 Å resolution to 
determine if crystal 
packing may have 
also contributed to 
its extended 
conformation (von 
Castelmur et al., 
2008). As can be 
seen in Fig. 2E, 
this construct has 
extensive packing 
interactions against its neighbors, and has correspondingly lower overall B-factors. Overlays of 
the same domain in 2RIK and 3B43 show that, while the tertiary structure of the Ig domains are 
virtually identical, the orientation of the Ig domains relative to each other vary (Fig. 4). We 
conclude that the overall shape of I6 observed in the 3B43 crystal structure is most likely 
dependent on crystal packing, not inter-protein domain-domain or domain-linker interactions. 
Figure 2. A) Cartoon representation of Ig65-70, colored by B-factor. Inset is 
the distribution of B-factors within the model. B) Linker region between Ig67 
and Ig68, showing a lack of interactions and electron density to keep the 
molecule rigid. C) Example of the extensive packing of Ig66 against its 
symmetry mate, denoted with *. D) Global view of the crystal packing of Ig65-
Ig70 relative to symmetry mates. E) Global view of the crystal packing of the 






 To examine 
the flexibility of titin 
Ig65-Ig70, we 
performed a series 
of MD and SMD 





conditions and the 
AMBER ff12SB 
force field showed 
that each domain 
displayed significant 
motions relative to 
its neighbor over 10 ns (Fig. 5). This is despite the Ig domains themselves being essentially static 
(average RMSD per domain over 10 ns is about 1.9 Å). This result agrees with similar 
experiments performed by Lee et al. (Lee et al., 2010). To further probe the stiffness of this 
section, we brought 
together the two ends of 
this structure together at a 
rate of 15 Å/ns, from 232 
Å to 141 Å. Analyses 
show that the straight part 
of the original structure 
(Ig67-Ig70) bent readily 
and that it required less 
than 0.6 kcal/mol of work 
(a rough cut-off for noise 
attributable to random 
thermal motion) to 
decrease the end-to-end 
distance to 200 Å (Fig. 
6A-C). Smaller-diameter 
models required progressively more work. These data suggest that while the last 4 domains are 
mobile relative to their neighbors, mobility only extends to roughly 140 degrees as measured 
from the center of mass from each domain, in agreement with previous data (Lee et al., 2010). At 
smaller angles, these Ig domains begin to run in to each other; thus, this molecule is intrinsically 
partially elongated. These data agree well with previously published MD bending data, as well as 
experimental SAXS data, showing that the average length of the I6 region is 220 Å (von 
Castelmur et al., 2008; Lee et al., 2010).  
Figure 3. Crystal packing between A) Ig69 and B) Ig70 and their respective 
symmetry mates (denoted with *). 
Figure 4. Alignment of Ig68 between the 2RIK (cyan) and 3B43 
(green) structure, showing that the neighboring Ig domains are in 





Here we re-analyze the Ig65-
Ig70 crystal structure and 
suggest that the X-ray data do 
not support the ‘carpenter’s 
ruler' model of titin in solution. 
Instead, these data agree with 
subsequent MD simulations 
showing that titin domains 
move mostly independently of 
each other, with only transient 
inter-domain or domain-linker 
interactions (Lee et al., 2010; 
Hsin et al., 2011). This is 
particularly evident in Ig68, 
whose dynamic movement 
makes it virtually invisible in 
the structure. The presence of 
motion in this region is likely 
caused by a lack of symmetry 
mates to pack against, resulting 
in higher-than-average B-
factors. 
 Our new model of Ig65-70 does not explain EM data that indicate that this region of titin 
is mostly elongated (von Castelmur et al., 2008). Several possibilities could explain this 
discrepancy. First, it could be that transient interdomain and domain-linker interactions, while 
weak, short-lived, and not present in the crystal structure, are present in sufficient quantities as to 
exert a substantial stabilizing force on the molecule. These interactions could be overwhelmed by 
thermal motion and crystal packing interactions and might not be seen in crystal structures. Such 
interactions are built into the mWLM and seem to fit the wet lab stretching data (Lee et al., 2010; 
Hsin et al., 2011). Previous SMD experiments had problems in explicit solvent with 
hydrodynamic drag (Lee et al., 2010). Thus, another possible explanation is that titin, once 
straight, tends to stay straight because of insurmountable solvent drag. Lastly, it may be that in 
the conditions under which EM experiments were conducted, titin is particularly amenable to 







Figure 5. Snapshots of MD simulations for I6 at A) 2 ns, B) 5 ns, 
and C) 9 ns of equilibration, showing the straightening and 
bending of the final four domains. The models were aligned from 




 MD simulations argue for a 
mWLM, yet previous a crystallography 
structure suggest a more rigid molecule. 
In this work, we identify crystal-packing 
artifacts as contributing to the apparent 
rigidity of the published crystal 
structure. Thus, the crystallography data 
in fact also suggest a dynamic system. 
This more nuanced view of the X-ray 
data reconciles this structure with the 












Figure 6. A) Force (in kcal/mol) v. distance (Å) graph 
of Ig65-70 (PDB 3B43). Images of Ig65-70 at B) 0 and 




Insight into the Auto-inhibitory Mechanism of the Second Kinase Domain of Obscurin 
 
Introduction 
 Obscurin isoform B is expressed in low levels in a wide variety of non-muscle tissues, 
including epithelial, brain, liver, pancreas, and kidney tissues (Ackermann et al., 2014; Russell et 
al., 2002; Stroka et al., 2016). This isoform of obscurin is unique in that it has two 
serine/threonine kinase domains located near its C-terminus (Russell et al., 2002). Interestingly, 
these kinase domains are the only direct signaling moieties in obscurin. Obscurin also contains a 
RhoGEF/PH tandem domain that activates RhoA. All of these three obscurin regions— the two 
kinase domains and the RhoGEF/PH tandem domain— are involved in cell adhesion and 
signaling. The obscurin kinase domains phosphorylate cadherins while the activation of RhoA 
causes downstream effects that influence integrin signaling (Hu and Kontrogianni-
Konstantopoulos, 2013; Stroka et al., 2016). Ultimately, the cellular consequences of these 
signals are increased cell adhesion and stress fiber formation.  
 Obscurin is normally associated with cytoskeleton stability and dynamics. Thus, these 
three obscurin signaling domains provide a strong link between the cytoskeleton and cell 
adhesion. Ablation of this link has considerable (but little-studied) physiological repercussions— 
obscurin is the second-most mutated gene in breast and colorectal cancers (Wood et al., 2007; 
Sjoblom et al., 2006; Stroka et al., 2016). Additionally, while non-tumorous tissue is rich in 
obscurin, biopsies of human breast cancer tumors have shown that obscurin is nearly absent in 
cancerous tissues (Stroka et al., 2016). Due to these findings, it is paramount to understand the 
mechanism of action of these signaling domains and how mutations affect the activation, 
expression, and/or functionality of obscurin. 
 The overall goal of this project is to obtain high-resolution crystal structures of both 
human obscurin kinases, KI and KII. However, this goal has run into several significant hurdles. 
KI does not express well. KII can be expressed, purified and crystallized, but this process is 
extremely inefficient— protocols recovered an average of 1 mg from 16L of bacterial culture. 
Therefore, in lieu of a crystal structure, we opted to model the KII domain using computer 
simulations. Although the obscurin kinase domains have not been well-studied, the structure and 
mechanism of activation of a similar kinase, the titin kinase, has been extensively studied 
(Mayans et al., 1998; Mayans et al., 2013). Like all kinase domains, the titin and obscurin 
kinases have two active sites that neighbor each other: a substrate binding site and an ATP-
binding site. These sites 
undergo cycles of activity and 
inhibition, depending on the 
needs of the cell, and as such, 
have highly specific 
regulatory and substrate 
recognition mechanisms 
(Mayans et al., 1998).  
 The titin and obscurin 
kinases are serine/threonine 
kinases; they phosphorylate 
Figure 1. Schematic showing the similarity between titin (left) and 
obscurin (right) kinase regions. All three kinases are preceded by 
an Ig domain (green), the titin kinase and KI are also preceded by 
an Fn-III domain (grey), and all three domains have an N-terminal 
tail (NL, yellow) and C-terminal tail (CL) in obscurin or C-terminal 





serine and threonine residues. The two domains have similar surrounding are modular and are 
linked to the rest of the molecule through a (presumably) unstructured N-terminal and C-terminal 
linkers (NL and CL, respectively) (Hu and Kontrogianno-Konstantopoulos, 2013; Mayans et al., 
2013) (Fig. 1). These domains are catalytically active; they can both auto-inhibit and auto-
activate themselves (Mayans et al., 1998; Hu and Kontrogianno-Konstantopoulos, 2013) (Fig. 2). 
This function is a hallmark of most kinases (Tsai and Nussinov, 2013).  
 In the context of the entire protein architecture, the obscurin domains mirror titin (Fig. 1). 
Preceding the titin kinase are an Ig domain, an Fn-III (Fn-3) domain, and the N-terminal tail 
(NL). Following the titin kinase are the C-terminal regulatory tail (CRD) and another Ig domain. 
Similarly, in obscurin, the first kinase is preceded by an Ig domain and NL, followed by the CL. 
The second kinase domain region is also similar in its organization; as it is preceded by an Ig 
domain, Fn-III domain, and NL, and immediately followed by its CL (Fig. 1). The CL is at the 
extreme C-terminus of obscurin and, therefore, there is no possibility of an Ig domain following 
the CL. 
 The titin kinase 
is usually inactive; structural 
studies have shown that the 
CRD wraps around the kinase 
domain and occludes the ATP-
binding pocket. In addition, the 
N-terminal region of the titin 
kinase can also bind at or near 
the active site. Together, these 
domains prevent ATP-binding.  
(Hu et al, 1994; Kobe et al., 
1996; Mayans et al., 1998; 
Gold et al., 2006) (Fig. 3). 
The titin kinase 
domain’s unusual auto-
inhibitory structure hints at its 
mechanism of action.  Titin 
acts like a molecular spring; 
when stretched, the 
mechanical stretch physically 
removes the NL and CRD 
from the titin active site, 
freeing it for substrate- and 
ATP-binding (Grater et al., 
2005; Puchner et al., 2008; 
Puchner and Gaub, 2010; 
Stahl et al., 2011). The  NL 
and CRD binding each 
effectively halves the catalytic 
activity and, therefore, the phosphorylation levels of the titin kinase. Together, the NL and CRD 
silence phosphorylation levels completely (Johnson et al., 2001; Masterona et al., 2011).  This 
Figure 2. Gel depicting the auto-phosphorylating nature of 
obscurin KII as well as its ability to phosphorylate cadherins 
(taken from Hu and Kontrogianni-Konstantopoulos, 2013). 
Figure 3. Lateral and frontal surface views of titin kinase showing 
the inhibited conformation. Note the position of the NL (yellow) 
and CRD (red) in relation to the active site, Δ (taken from Mayans 




mechanism is the only known mechanism of how the cytoskeleton directly acts as a 
mechanosensor- titin stretch results in target phosphorylation through the release of this auto-
inhibitory mechanism. 
Given that obscurin and titin have a similar overall architecture, perform similar 
connecting functions within the cytoskeleton, and contain similar kinase domains, we 
hypothesize that the kinase domains also are stretch-activated mechanosensors. As a first step to 
testing this hypothesis, we must determine whether the NL and CL regions of the obscurin kinase 
domains interact with the kinase domains. Towards this beginning goal, we took a two-pronged 
approach. To further investigate the auto-inhibitory mechanism of KII, the recombinant domain 
was purified and crystallized. From these crystals, the high-resolution crystal structure KII will 
be solved, though work is still in progress. Parallel to this wet-lab work, we also study computer 
simulations of KII. Herein, I describe the binding affinity studies performed on a simulated 
model of KII obtained by using titin’s kinase as a model structure. The data indicate that, 
although the N-terminal tail of KII cannot bind to the active, site, the C-terminal domain appears 
to bind. 
 
Materials and Methods 
Purification of Obscurin KII. Protein samples derived from a pet-24a(+) construct containing a 
codon-optimized human obscurin KII domain were expressed in E. coli and purified as follows: 
Starter cultures (~5mL) of KII were made following addition of glycerol stock (500 μl KII 
pET24a BL-21 cells into 50/50 glycerol) and 10 μl of kanamycin. Starter cultures were shaken 
overnight at 37°C, 250 rpm, then added to 1 L flasks of LB (10 g tryptone, 5 g yeast extract, 5 g 
NaCl, in 1L dH2O), along with 1 mL kanamycin. These flasks were shaken at 37°C, 250 rpm. 
Induction occurred ~3 hours later, at 0.6-0.8 OD600, with the addition of 0.2 g isopropyl β-D-1-
thiogalactopyranoside (IPTG). Approximately 3 hours later, flasks were taken out of the 
incubator/shakers and centrifuged using a JLA 16.250 rotor at 6000 rpm, 4°C for 15 min. The 
supernatant and pellet were separated and the pellet was kept at -80°C until ready for further 
purification. Pellets were resuspended in His-tag binding buffer ((50 mM NaH2PO4, pH 8.0, 0.3 
M NaCl, 100mM imidazole)) and 100 μl phenylmethane sulfonyl fluoride or 
phenylmethylsulfonyl fluoride (PMSF) was added to prevent degradation during sonication at 
100% amplification, 15 s pulse, for 30 min, then centrifuged using a JA 25.50 rotor at 14000 
rpm, 4°C, for 30 min. The resulting pellet underwent two cycles of 8 M urea resuspension and 
centrifugation under the same conditions as described previously. PMSF (100 μl) was added to 
the resulting supernatant, which was then dialyzed in a buffer containing 50 mM NaCl and 20 
mM Tris pH 7.5 at 4°C for 2-3 hours. This solution was centrifuged again using a JA 25.50 rotor 
at 14000 rpm, 4°C for 30 min, then the supernatant was run over a Nickel column. The eluent 
was concentrated in a 5K concentrator tube via centrifugation at 4500 rpm, 4°C for 90 min 
intervals until less than 1 mL solution remained, then run over a size exclusion column. Contents 
of column fractions were visualized using gel electrophoresis; fractions containing KII were 
pooled and concentrated. The concentration of KII in the resulting solution was obtained using a 
Thermo Scientific Nanodrop 2000 Spectrophotometer using the extinction coefficient (42330 




Crystallization. The hanging drop method with various crystallizing solutions was used to obtain 
KII crystals. Crystals were harvested and frozen in liquid nitrogen until X-ray diffraction 
analysis using a glucose cryoprotectant. 
Model Creation and Verification. The sequence of KII was modeled using PHYRE homology 
modeling. Verification of the model was performed in YASARA under explicit solvent 
conditions for ~15 ns (Krieger et al., 2014; Krieger et al., 2004). The N-terminal and C-terminal 




Active Site Determination. Active residues in KII were determined via COACH analysis 
protein/ligand binding site prediction meta-server (Yang et al., 2013) (Fig. 4). 
N-terminal Binding Affinity Tests. The NL was modeled by hand as a random coil in YASARA 
and allowed to equilibrate for ~10 ns (Krieger et al., 2014; Krieger et al., 2004). The N-terminal 
tail and KII domain were the run through HADDOCK2.2 web docking prediction interface 
server (van Zundert et al., 2016). Ligand 1 was KII, with active residues as predicted by COACH 
and ligand 2 was the N-terminal tail. 
C-terminal Binding Affinity Tests. The CL of KII was modeled by taking the PHYRE model and 
fusing it to the C-terminal regulatory domain of titin. The titin sequence was then swapped out 
and replaced with the obscurin KII sequence. The CL and KII domain were the run through 
HADDOCK2.2 web docking prediction interface server (van Zundert et al., 2016). Ligand 1 was 
KII, with active residues as predicted by COACH. Ligand 2 was the CL. Five runs were run in 
total with each run marking a different active segment of the CL. Runs were structured to run 10 
CL residues as active with each sequential run overlapping by four residues. For the purposes of 
these tests, only the first 26 residues of the CL were tested; the CL wraps almost entirely around 
the main chain of KII and it would be nearly impossible for the residues directly behind the 







Figure 4. Sequence of KII showing active residues (magenta), NL (yellow), and CL (red). 
Sequence of KII obtained from PubMed obscurin isoform B, where numbers to the left indicate the 






 The obscurin KII model was made using the PHYRE homology program with the titin 
kinase as a template (Fig. 5A). The original PHYRE-based model is seen in Fig. 5B. To verify 
the stability of this model, the model was equilibrated for 15 ns in explicit solvent at 310K using 
YASARA. At this point, no 
significant conformation 
changes were observed and the 
ATP-binding pocket remained 
intact (Fig. 6). The average 
structure and last structure, 
shown overlaid in Figure 5, 
have an RMSD of 1.436. 
Therefore, this equilibrated 
model was deemed of 
sufficient quality to move 
forward with binding affinity 
simulations. 
 Following structure 
validation, the N-terminal tail 
was modeled by hand using the add residue function in YASARA. This procedure was chosen 
due to the small size of the NL; it is only 20 residues and is not predicted to have any regular 
secondary structure. Therefore, a random coil, allowed to equilibrate in solution, was a good 
starting point for initial binding studies. The NL and 
KII were then sent through a HADDOCK prediction 
binding web server to determine the likelihood of 
binding between the N-terminal tail and the active site 
of KII. HADDOCK is an information-driven flexible 
docking approach that predicts binding energies from 
predicted protein interfaces using ambiguous 
interaction restraints. Thus, this is an off-shoot of other 
ab initio binding algorithms. As an output, 
HADDOCK primarily uses a Z-score. This number 
represents the separation from the mean of all clusters 
tested. Thus, the lower the Z-score, the better a certain 
target docks into the protein binding site, as measured 
against a random insertion event (van Zundert et al., 
2016). 
 While the RMSD for NL binding to KII is large, the overall Z-score is moderately good, 
suggesting that the NL can bind to the kinase domain.  However, close examination of the 
structure reveal that these models require the removal of a critical beta strand in the kinase 
domain in order to bind.  Given that this strand is a central part of the kinase domain, we suspect 
that this binding event would not occur in reality. HADDOCK runs with this beta strand intact 
demonstrate poor binding. (Fig. 7A-C). Similar results were obtained with an increased size in 
the KII binding pocket, indicating that even a large binding area did not improve NL binding. In 
Figure 5. A) Cartoon representation of titin kinase showing the 
(yellow), CRD (red), and active residues (taken from PDB). B) 
Model of KII showing active residues (magenta), CL (red), and NL 
(yellow).  
Figure 6. Average (green) and last (cyan) 
structures obtained from the YASARA 
verification of the KII model during ~15 ns 





total, these data strongly suggest that, despite its close proximity, the N-terminus does not 
substantially interact with the KII active site (Fig. 7A-C). 
 Although the 
N-terminal tail 
could not bind to 
KII’s active site, 
this would not 
necessarily be the 
case for the CL. 
This tail is longer 
than the N-terminus 
at 44 residues. This 
long region 
precluded modeling 
by hand. Since this 
tail may act similar 
to the titin domain, 
the CL sequence 
was threaded 
through the titin 
CRD Structure. As 
the CL begins on 
the opposite side of 
the molecule from 
the active site, only 
the end of this 
stretch was tested. 
Proximal residues 
would be to far 
away to bind to the 
active site. 
We tested 
this binding in two 




through the titin 
CRD region and 
docked this onto 
our obscurin KII 




Figure 8. A) Model of KII (cyan) and C-terminal tail (red). B) HADDOCK 
results for the test of KII ATP-binding site with residues 4-14 of the CL 
showing Z-score vs RMSD showing small, stable RMSD between the two 
structures. The structure shown in A is Cluster 2, displayed by blue triangles in 
the plot. 
Figure 7. A) Model of KII (cyan) with all β-strands intact. The NL not shown to 
more clearly see all five β-strands. B) Model of KII (cyan) and NL (yellow) 
after the fifth β-strand was removed. C) HADDOCK results of Z-score vs 
RMSD showing large, variable RMSD between the two structures. The 




using YASARA for 50 ns. Analysis from this simulation indicated multiple regions of the 
obscurin CL could bind to our KII model. Next, we took overlapping sequences of the KII CL 
and performed HADDOCK runs into the KII active site, in a similar way to how we tested the N-
terminal region. In total, 5 separate KII/CL runs were completed, each considering 9 possible 
clusters. Consecutive runs differed in the ‘active’ region of the CL, beginning with the first ten 
residues and overlapping by 4 residues each time. In other words, residues 1-10, 4-14, 8-18, 12-
22, and 16-26 were run separately. HADDOCK results consistently predicted binding between 
the CL and KII’s active site with low RMSDs and reasonable Z-scores (generally >-1.7) (Fig. 8). 
The run in Figure 8 considered the ATP-binding site and residues 4-14 of the CL as active and 




 HADDOCK analysis determined that the NL was able to bind to the active site of KII but 
only if there was significant displacement of the fifth β-strand, which is unlikely due to the 
extensive hydrogen-bonding amongst β-sheets. Binding occurred via electrostatic interactions 
between the KII active site and NL when this fifth β-strand was removed. Consistent binding was 
observed between the CL and the active site, as shown by HADDOCK analysis. This binding 
occurred electrostatically between the ATP-binding site of KII and the CL and is presumably 
similar in nature to that of the CRD binding to the ATP-binding site of the titin kinase. However, 
the in vivo and in vitro validity of the obscurin KII/CL binding event has yet to be tested. If the 
binding is relatively strong, then it is likely that the CL has some inhibitory nature on the active 
site. If not, then KII must be auto-activated and auto-inhibited by some other mechanism. Given 
that not all proteins in the titin-like family are activated in the same manner as each other, nor as 
titin itself (Mayans et al., 2013; Greene et al., 2008), coupled with our findings regarding the NL 
and KII, this possibility may be even more likely as the possibility that obscurin and titin kinases 
hold similar mechanisms of activation. 
In the future, we hope to quantify the strength of the KII/CL binding using YASARA to 
determine how much force is required to break the electrostatic bond between the two structures. 
To complement this computer research with wet-lab work, we will design and implement an 
affinity column to test the affinity of the CL for the kinase domain as well as the ability of the 
CL to displace substrate and/or ATP from the active site(s) of KII. Lastly, we will continue to 






Appendix A: Methods for Additional Projects 
 
Materials and Methods (KI) 
Purification of Obscurin KI. Protein samples of pet-24a(+) human obscurin KI were expressed in 
E. coli and purified through the following procedure. Pet-24a(+) KI was transformed onto BL-21 
cells and starter cultures (~5mL) of KI were made from these with the addition of 10ul of 
kanamycin. Starter cultures were shaken overnight at 37C, 250rpm, then added to 1L flasks of 
LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to volume with diH2O), along with 1mL 
kanamycin. These flasks were also shaken at 37C, 250rpm. Induction occurred ~3hr later, at 0.6-
0.8 OD, with the addition of 0.2g IPTG. Approximately 3hr later, flasks were taken out of the 
incubator/shakers and centrifuged using a JLA 16.250 rotor at 6000rpm, 4C for 15min. The 
supernatant and pellet were separated and the pellet was kept at -80C until ready for further 
purification. Pellets were resuspended in G75 buffer (20 mM Tris pH 7.5, 50 mM NaCl, diH2O), 
100ul PMSF was added to prevent degradation during sonication at 100% amplification, 15s 
pulse, for 30min, then centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min. The 
resulting pellet was resuspended in 8M urea and centrifuged under the same conditions as 
described previously. PMSF (100ul) was added to the resulting supernatant, which underwent 
fast dialysis 20mL of G75 buffer at (4°C). This solution was centrifuged again using a JA 25.50 
rotor at 14000rpm, 4C for 5min, then the supernatant was run over a Nickel column. All 
fractions of the Nickel column were visualized using gel electrophoresis. 
 
Materials and Methods (Rho-GEF) 
Purification of Obscurin Rho-GEF. Protein samples of pet-24a(+) human obscurin Rho-GEF 
were expressed in E. coli and purified through the following procedure. Pet-24a(+) Rho-GEF 
was transformed onto BL-21 cells and starter cultures (~5mL) of Rho-GEF were made from 
these with the addition of 10ul of kanamycin. Starter cultures were shaken overnight at 37C, 
250rpm, then added to 1L flasks of LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to volume 
with diH2O), along with 1mL kanamycin. These flasks were also shaken at 37C, 250rpm. 
Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG. Approximately 3hr 
later, flasks were taken out of the incubator/shakers and centrifuged using a JLA 16.250 rotor at 
6000rpm, 4C for 15min. The supernatant and pellet were separated and the pellet was kept at -
80C until ready for further purification. Pellets were resuspended in His-tag binding buffer 
((500mM NaH2PO4, pH 8.0, 3M NaCl, 100mM imidazole for 10x)) and 100ul PMSF was added 
to prevent degradation during sonication at 100% amplification, 15s pulse, for 30min. Then the 
solution was centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min and the supernatant 
was run over a Nickel column followed by a DEAE column. The eluent from the DEAE column 
was visualized using gel electrophoresis and then concentrated in a 5K concentrator tube via 





Materials and Methods (Rho-GEF-PH) 
Purification of Obscurin Rho-GEF-PH. Protein samples of pet-24a(+) human obscurin Rho-
GEF-PHwere expressed in E. coli and purified through the following procedure. Pet-24a(+) Rho-
GEF-PH was transformed onto BL-21 cells and starter cultures (~5mL) of Rho-GEF-PH were 
made from these with the addition of 10ul of kanamycin. Starter cultures were shaken overnight 
at 37C, 250rpm, then added to 1L flasks of LB (10g tryptone, 5g yeast extract, 5g NaCl, dilute to 
volume with diH2O), along with 1mL kanamycin. These flasks were also shaken at 37C, 250rpm. 
Induction occurred ~3hr later, at 0.6-0.8 OD, with the addition of 0.2g IPTG. Approximately 3hr 
later, flasks were taken out of the incubator/shakers and centrifuged using a JLA 16.250 rotor at 
6000rpm, 4C for 15min. The supernatant and pellet were separated and the pellet was kept at -
80C until ready for further purification. Pellets were resuspended in His-tag binding buffer 
((500mM NaH2PO4, pH 8.0, 3M NaCl, 100mM imidazole for 10x)) and 100ul PMSF was added 
to prevent degradation during sonication at 100% amplification, 15s pulse, for 30min. Then the 
solution was centrifuged using a JA 25.50 rotor at 14000rpm, 4C for 30min and the supernatant 
was run over a Nickel column followed by a DEAE column. The eluent from the DEAE column 
was visualized using gel electrophoresis and then concentrated in a 5K concentrator tube via 










Step 0: Open HKL2000 
Open a terminal window, go all the way up in directories. Then go through ‘usr’ to ‘local’ to 








Step 1: Load Data 
Once HKL2000 has opened fully, look under the space titled ‘directory tree’ and click on 
‘berndsce,’ ‘Desktop,’ ‘APS4102014,’ then on the data folder you will be working on (eg. 
‘JMU113’ or ‘JMU211’).  
 
Designate your input folder, which is the data folder you just chose. This is where HKL will scan 
for data files. Create or assign where the output files will go and click ‘load data sets.’ To create 
a new folder, click ‘Create Directory’ and type the name.  
 
Click ‘Load Data Sets.’ You will choose the file with ‘data’ in the name, and NOT with ‘scan’ in 
the name. Once this has opened, record your wavelength and frame width. Then, click on the tab 
entitled ‘Index.’ 
 
If there is more than one data set, you will have to do run HKL twice, once with each data set. 
DO NOT try to do one HKL using both data sets. You can merge them later in CCP4. 
 
Step 2: Indexing 
Click on ‘fit basic’ and make sure that there are exactly 6 red boxes. Set resolution maximum to 
‘corner’ if you think there is data that was not included and to ‘edge’ if you only want to go to 
the user set boundaries of the original data. For Synchrotron data, ‘corner’ is more appropriate. 
The minimum resolution should be 50.00. Click on ‘Peak Search,’ then, in the new window that 
appears, click on ‘Peak Sear,’ and minimize the random peaks. This will usually involve 
lessening your peaks until they fall within the range 300-800. Record the number of peaks. Once 
this is done, click ‘OK’ then ‘Index.’ 
 
Step 3: Choosing a Space Group 
When the window appears for you to choose a space group, choose the group that has the highest 







Step 4: Refining 
Your χ2 values should be less than 2. Click ‘Refine’ and continue to refine until your χ2 values 
level out (are constant). At this time, the ‘Integrate’ button should be green (ideally).  If it is, 
press it. 
 
If not, click ‘Fit All’ then ‘Refine’ again until the χ2 values level out. You may also need to 
change you space group, the values of which will have change due to your refining. Click 
‘Bravais Lattice’ to open up your space group options. Again, choose the one with the most 
symmetry. If you do change your space group, you will need to refine again. Record the space 
group at the top of this screen. ‘Integrate’ should be green now, so press it.  
 
Step 5: Integrate 
Your mosaicity value should be less than 1. Record both it and your resolution range. Ideally, the 
graph on the left should look like one downward slope while the graph on the right should be 
fairly constant. Record your positional, partiality, X- χ2, Y- χ2, and χ2 values. 
 
Step 6: Scale 
Click on the ‘Scale’ tab at the top and make sure your space group matches with the one you 
previously chose. Make sure that the box next to ‘Small Slippage, Imperfect Goniostat’ is red. 
Click ‘Fix B’ and make sure that ‘Write Rejection File’ is red also. Then click ‘Scale Sets,’ 
which should be green.  
 
Pay close attention to the graphs titled Completeness vs. Resolution and I/Sigma and CC1/2 vs. 
Resolution. These will aid you in determining the minimum value of your resolution. On the 
Completeness vs. Resolution graph, move your cursor to where the blue line begins to drop and 
remember this number. Scroll down to the CC1/2 vs. Resolution graph and move your cursor 
along the grey limit to where the grey meets the blue. This number should match up fairly 
decently with the number from before. However, to be more accurate, click on the ‘Show Log 
File’ button at the bottom and scroll down on the window that opens to the bottom. Compare the 
values in the Average I column to those in the Average error column and record the Shell lower 
limit for the line in which the Average I is approximately 2 times that of the Average error. This 
will be the minimum value of your resolution. Hit ‘Close’ on this window when done, set your 
minimum resolution, and the maximum for 50. 
 
Click ‘Delete Rejection File’ then ‘Scale Sets.’ 
 
Record a, b, c and alpha, beta, gamma. 
 
Your output file will have the name output.sca and will be wherever you specified it to go in the 




Step 0: Opening CCP4 
From the Finder, go to ‘Applications,’ then ‘ccp4-6.4.0’ and ‘ccp4.’ (If it is not already down on 




Step 1: Running CCP4 
On the right side of the screen there is a program list. Under ‘Data Reduction and Analysis,’ 
click ‘Symmetry, Scale, and Merge (Aimless).’  
 
In the window that pops up, make sure that ‘Option to skip scaling & just merge’ is black. Also, 
make sure the FreeR column has 0.05 in the blank and that ‘Copy FreeR from another file’ is 
grey. Change the Input reflection file type to ‘Scalepack file’ and choose your input/output 
destinations. SCA #1 is your input. You must input the ‘output.sca’ file, NOT the ‘scalepack.sca’ 
file. 
 
HKLOUT is where you type/choose the output destination. When choosing your output 
destination, you will have to name the file. To do this, choose the folder destination, click ‘OK’ 
and then add to the blank a /_____.mtz where the ____ is the desired file name. Then click ‘Run’ 
and ‘Run Now.’ 
 
If the process is finished quickly, chances are that you did something wrong. It should at least 




Step 0: Opening Phenix 
Go to the ‘Finder’ icon and click ‘Applications,’ ‘Phenix 1.8.4.’ This will open the Phenix Home 
window. 
 
Step 1: Select Project 
You will need to create a new project file that will store your data. On the Phenix Home screen, 
click ‘New project,’ then give the project an ID and a directory. There can only be one project 
per directory, so you may need to create a new folder in Finder that will become your directory. 
When done, click ‘OK’ and make sure there is a green check by your new project ID. If there 
isn’t one, double click on the ID. 
 
Step 2: Xtriage 
On the right side of the Phenix Home screen, look under ‘Reflection tools,’ and click on 
‘Xtriage.’ In the bar next to ‘Reflections,’ you will browse to find the .mtz file you created in 
CCP4. Then click ‘Run.’ 
 
In the new tab, there will be a subtab called ‘Twinning analysis.’ Click this and scroll down to 
‘Likely point groups.’ Choose your point group and record it in your lab notebook. Then, save 
the file with a file name as ____reindexed.mtz where ___ is the desired name of the file. MAKE 
SURE TO ADD THE .mtz TO THE END. 
 
Step 3: Molecular Replacement 
Back at the Phenix Home window, under ‘Molecular replacement,’ click on ‘Phaser-MR (simple 
interface).’ Add your reindexed file by clicking ‘Add file.’ It should be in a folder labeled 





Put 95 in the ‘Sequence identities’ bar then look under  
‘Search options.’ Here, change ‘Also try alternative space group(s)’ to ‘All possible in same 
point group.’  
 
You will also need to add a .pdb file, which will be your input model. Click ‘Run’ and ‘Run 
locally.’ When Phenix has finished, click ‘Run phenix.refine.’ 
 
Step 4: Refining 
In ‘Refinement settings,’ make sure the following are checked: ‘XYZ coordinates,’ ‘Real-space,’ 
‘Rigid body,’ ‘Individual B-factors,’ ‘Automatically correct N/Q/H errors.’ All else should be 
left unchecked. 
 
If this is your first time refining, under ‘Input data’ go to Options…’ and make sure that 
‘Generate new R-free flags’ is checked. Also, change ‘Fraction of reflections in test set’ is .05. 
 
If this is your second time refining, you should check ‘TLS parameters,’ ‘Simulated annealing 
(Cartesian),’ and ‘Simulated annealing (Torsion angles)’ under the ‘Refinement settings’ tab. 
You will also need to go back to ‘Options…’ and uncheck ‘Generate new R-free flags.’ Also, 
you will replace the .mtz file from Xtriage and instead use the file ending in ____data.mtz as 
your new X-ray data file. 
 
Once you have refined significantly, you may want to do the following... 
 Uncheck ‘Rigid body,’ which will rotate your structure within the electron density. Do 
this if you find that, when refining, the computer flips or turns you structure in a way you don’t 
want it to. 
 Check ‘Optimize X-ray/stereochemistry weight’ and ‘Optimize X-ray/ADP weight,’ 
which will have the program put more emphasis on the data you already have. 
 Uncheck both ‘Simmulated annealing…’ once your loops are in good shape, as this part 
checks your loops. 
 Check ‘Update waters’ to put in waters to your structure. ONLY do this when your 
structure is as good as you can get it (or near so). In other words, only towards the end of 
refinement. 
 





The figure below shows the electron density map for the protein. You need to make the sequence 
fit into the blue or green parts of the map. To do this follow the steps provide below.  
 
 
Step 0: Opening a Structure in Coot 
Click on ‘Open Coords…’ and select the .pdb file you received in the above steps. It will 




‘File’ then ‘Open Coordinates’ and selecting your .pdb file. This will open the chain of amino 
acids. 
 
You will then need to open up the electron density map. To do this, click on ‘File,’ then ‘Auto 
Open .mtz’ and select the .mtz file that does NOT contain data in the name. 
 
Go to ‘Draw,’ then ‘Cell and Symmetry,’ ‘Yes,’ ‘Show,’ and ‘Apply’ to show the unit cells. 
 
Step 1: Basic Coot 
Right clicking and scrolling will allow you to zoom in and out of your structure. 
 
Left scrolling will allow you to change how much electron density it shown. The numerical value 
will be displayed at the top of the structure picture. You should operate within the 1.5-2 range of 
these values. 
 
Left clicking on an amino acid will label it. To remove labels, go to ‘Measures,’ ‘Distances and 
Angles’ and click ‘Clear All Atom Labels.’ 
 
Left clicking and dragging will allow you to rotate the x-, y-, and z-axes around the center of 
your screen, which is represented by a pink square in the center of Coot. 
Holding down the control button on your keyboard while left clicking and dragging will allow 





When you are manually fitting the sequence into the density map, you want to get the sequence 
into the blue or green density as shown above. When there is red density, this means that the 
sequence is not favorable to be in that area. You want to AVOID the red density*. The blue 
density is the occupied area that is acceptable.  
 
*When there is red density within your blue density, to use Dr. Berndsen’s words, “cry.” There is 
not much you can do here except use the ‘Real Space Refine Zone’ feature to move it out of the 
way as best as possible. This feature will auto fit your amino acid to the electron density map. 
 
Step 2: Navigating the Structure 
 
To move from amino acid to amino acid, select the ‘Go To Atom’ under the ‘Draw’ pulldown 
menu. This will allow you to move throughout the sequence one amino acid to the next. If there 




The ‘Go To Atom’ screen looks like the figure above. You can move forward in the chain by 





An easier way to do this is to go to ‘Draw’ then ‘Sequence View’ and your .pdb file. This will 
display the entire chain in a window. Moving this window to the side will allow a quick jump 




Step 3: Real Space Refine Zone 
The ‘Real Space Refine Zone’ may be the most helpful tool that Coot has to fit your structure. 







The ‘Real Space Refine Zone’ will auto fit an area that you select. This will get the angles and 
bonds in optimal orientations for the sequence. To select one amino acid to refine, double click 
on some part of the amino acid. To select a larger region, single click on each side of the region. . 
Dragging an amino acid or region will allow you to finagle the region where you want it. It is 
easiest to grab the region by clicking and dragging from a “corner” or “bend” of the region. You 
will then have to accept or reject the refinement. Ideally, all of the categories below will be 
green. 
 
Once the bonds and angles are in the optimal orientation press the accept button to keep the 
changes you made on the structure. Use discretion to determine whether or not an orientation is 
suitable. It is more important to match an amino acid to the given electron density than it is to 
have the orientation be optimal (have everything be green). 
 
There will be many green and blue regions surrounding the atom where waters, calcium, etc. will 





‘Regularize Zone’ is similar to ‘Real Space Refine Zone’ but may make more drastic changes. If 
you are having a lot of difficulty with a region, this may be good place to go as more of a last 
resort and may point you in the right direction. 
 
Step 4: Mutate and Auto Fit 
If you want to change an amino acid, use the ‘Mutate & Auto Fit’ button from the side menu that 
is shown above then select the amino acid you want to change it to. This can also be done with 
the ‘Simple Mutate…’ feature, but this will not fit the amino acid to your electron density. 
 
Step 5: Add Terminal Residue 
If there is an amino acid missing from the sequence you can add in an amino acid by using the 
‘Add Terminal Residue’ button. After clicking it, click on the terminal carbon of your structure 
and then on ‘Accept’ in the window that pops up. Make sure that the added amino acid (it will be 
faded grey) is inside the electron density on your screen (you can move it by clicking on the grey 
amino acid and dragging it) before hitting ‘Accept.’ 
 
If the amino acid appears and is not connected to the rest of your chain, simply click ‘Real Space 
Refine Zone’ and select an area containing the terminal residue and the newly added amino acid. 
The amino acid should then connect. 
 





To view the Ramachandran Plot, go to Validate, then Ramachandran Plot, then click on the .pdb 
file that you would like to view in the Ramachandran plot. You need to check the Ramachandran 
plot before you run the comprehensive validation because to have a good structure meaning that 
all the amino acids are in the pink regions on the Ramachandran plot. 
 
 
As shown in the Ramachandran plot, all the residues need to be in the pink regions (ideally). If 
they are not you need to move the residue into the pink region, or at least the yellow region. 
When hovering your mouse over a square or triangle, it will show which amino acid that shape 
relates to. Those amino acids with squares have different Ramachandran favored regions than 
those with triangles.  
 
For a structure to be considered good, you need to have zero “Ramachandran outliers” and 
minimal “in allowed regions” (maximum in “favored” regions). Once you have checked this plot 
than you can go forward with validating your structure.  
 
A red shape means that the amino acid is a Ramachandran outlier, and should be fixed. A blue 
shape means that the amino acid is not an outlier, although it may or may not be in the favored 
region. A green shape represents the amino acid you currently have your screen’s focus on. Note 
that fixing an amino acid may involve moving the amino acids immediately before and after it. 
To fix or move an amino acid’s configuration, you can use the ‘Real Space Refine Zone,’ 
‘Regularize Zone,’ or ‘Edit Backbone Torsions.’ All of these can be found on the right side of 
the Coot window, and ‘Edit Backbone Torsions’ may be the most helpful. 
 
Step 7: Edit Backbone Torsions 
Once in the ‘Edit Backbone Torsions’ window, you can either rotate from the peptide or the 
carbonyl. Note that this will change the Ramachandran plot for both the amino acid you are 
rotating and the one(s) around it. Try to get both shapes in the desired pink region, but make sure 






Step…: Check/Delete Waters 
When you have refined a structure using the ‘Update Waters’ feature in the refinement settings, 
the program will place waters in spots they do not actually belong. One way to check whether or 
not these are likely water spaces, click on ‘Validate,’ then on ‘Check/Delete Waters’ and ‘OK.’ 
This will bring up a small window in which questionable waters are displayed. Check to see if 
the waters in these spots are too close or have too small of an electron density to constitute true 
waters. Note that there may be more incorrect waters than those in the questionable water 
window and that not all of the questionable waters may be incorrect. Use your best abilities to 
discern whether or not there should be waters in each place. 
 
Back to Phenix: Generating Table 1 
 
Step 0: Opening Table 1 
On the Phenix home page, navigate to the project you for which you wish to generate a Table 1. 
This will give you many values of your structure, including the Rfree, Rwork, correlation 
coefficient, resolution, and percent completeness. Under the ‘Utilities’ tab on the Phenix 
homepage, click ‘Generate “Table 1” for journal.’ Under the ‘Options’ tab that pop up, make 
sure that ‘CSV’ is checked. A .csv file is compatible with Excel and will allow you to view it 
there. In the ‘Structure data’ tab, designate the .pdb file, .mtz file, and unmerged data. 
 
Step 1: Unmerge Data 
To get an unmerged file of your data, you will need to run HKL2000 again on that project. Run 
HKL2000 normally as you did before. Then, after you have scaled your sets (you may want to 
put these output files into a different folder or name them something different to tell the 
difference between your previous ones), go to the ‘Macros’ tab and input the follow macro to 
both the ‘During Integration’ and ‘During Scaling’ lines: no merge original index    You will 
have to click ‘Add Macro’ when done. 
 
Then, delete the rejection file and re-scale your sets. You will get a message that says something 
along the lines of ‘unable to read file… may be because of no merge.’ This is fine since you did 
ask HKL to not merge. 
 




If you had more than one data set for this project, you will again have to run HKL twice and get 
two unmerged output files. Like before, you will merge them using CCP4. 
 
Open CCP4 and open ‘Symmetry, Scale, Merge (Aimless).’ Then, in the Aimless window, make 
sure that ‘Option to skip scaling and just merge,’ ‘Customize output options,’ ‘Assign to the 
same dataset as the previous file,’ and ‘Cell Dimensions’ are checked.  Change ‘Input reflection 
file type’ to ‘Scalepack file.’ Change ‘MTZ Output’ to ‘scaled, unmerged & no outliers’ and 
change ‘Scalepack Output’ to ‘No output.’ You should have SCA #1 and SCA #2 available for 
input. Choose your files, set your cell dimensions, and click ‘Run’ and ‘Run Now.’ 
 
This will be the ‘Unmerged data’ file in Phenix for generating the Table 1. 
 
Step 3: .pdb and .mtz for Table 1 
Your .pdb file will be that of your best refinement. The .mtz file will be the data.mtz file that you 
used to refine your .pdb file against. If you can’t remember which ones these were, you can view 
it by doing the following. Under the ‘Job history’ tab of Phenix home, double click your best 





Appendix C: Tutorial on How to Make Publication Quality Images in PyMOL 
 
Command Description 
Color grey50, map Colors the electron density map grey 
Set mesh_width, 0.5 Sets the width of the electron density map 
mesh 
Bg_color white Sets the background color to white 
Set ray_trace_fog, 0 Turns off fog 
Set depth_cue, 0 Turns off depth cues 
Ray Produces a rayed image 
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